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ABSTRACT 
 
 
Recently, discovery of microRNA has provided new insights into cancer research, revealing 
the role of miRNAs in various biological processes, and evidence shows that their 
deregulation in many cancers has prognostic and predictive significance. Although specific 
miRNAs have been discovered in the malignancies studied in this thesis:  colorectal cancer 
(CRC), giant cell tumor of bone (GCTB), acute lymphoblastic leukemia (ALL), and acute 
myeloid leukemia (AML), very little still is known about the association of miRNAs with 
progression and their response to treatment. By applying novel microarray techniques, we 
profiled miRNA expression in CRC, GCTB, ALL and, AML. 
In the study focusing on primary tumors of 60 metastatic CRC (mCRC) 
patients, we detected BRAF mutations in 5 and KRAS mutations in 15 cases. In addition to 46 
altered miRNAs in mCRC patients with and without KRAS mutation vs. normal colon tissue, 
we observed an miRNA signature associated with KRAS status when we compared 15 
patients with mutant KRAS with 40 patients without this mutation. Four differentially 
expressed miRNAs, over-expressed miR-92a, miR-127-3p, miR-486-5p, and under-expressed 
miR-378, were evident in the mutated KRAS group vs. wild-type KRAS group. 
In another study on CRC, miRNA profiling in primary tumors of 33 mCRC 
patients with wild-type BRAF and KRAS allowed identification of miRNAs related to their 
response to anti-EGFR monoclonal antibody treatment. We found up-regulated miR-31* and 
down-regulated miR-592 in progressive disease (PD) compared to that in disease control 
(DC). Evaluation of mRNA levels of SLC26A3 and ATN1, drug-related genes and of miR-
31* target genes showed their lower level of expression in PD vs. DC. Moreover, correlation 
between overall survival and miRNA expression assessed by two approaches, cluster analysis 
and the Cox proportional hazard regression model, revealed two common miRNAs, miR-
140-3p and miR-1224-5p, to be related to survival in both analyses.  
As for the study of the metastatic and non-metastatic GCTBs, we found 12 
miRNAs as being differentially expressed (miR-136, miR-513a-5p, miR-494, miR-224, miR-
542-5p). Expression levels of eight genes such as NFIB, TNC, and FLRT2 correlated 
inversely with miRNA results. The expression levels of miR-136 and its target gene, NFIB, 
were verified by use of qRT-PCR. The level of NFIB protein also was higher in metastatic 
than in non-metastatic GCTBs. Further, we tested the protein expression level of NFIB in an 
independent validation cohort of 74 primary archival GCTB specimens to assess the power of 
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NFIB as a prognostic marker. Immunodetection showed a higher frequency of NFIB over-
expression in primary tumors that developed metastases than in the disease-free group. 
Moreover, we studied the miRNA expression profiles of primary tumors of 90 
bone marrow core biopsies of ALL patients, including 11 patients with paired samples at 
diagnosis and at relapse. We found a set of miRNAs (miR-1281, miR-1225-3p, miR-877*, 
miR-423-5p, miR-29c) significantly related to survival (q<0.05). Further validation of miR-
423-5p expression by qRT-PCR confirmed microarray analysis results and showed a direct 
correlation with survival. In comparisons between the diagnosis-relapse pairs, expression of 
miR-654-5p and miR-431 between the two groups significantly differed, and these miRNAs 
were down-regulated in relapse samples. 
Comparison of miRNA profiling of 15 chemorefractory and 18 chemosensitive 
AML patients showed that the differentially expressed miRNAs were miR-363, miR-532-5p, 
and 342-3p, all of which were over-expressed in chemorefractory vs. chemosensitive patients. 
Verification by use of qRT-PCR of both miR-363 and miR-532-5p revealed similar results as 
with microarray. The miR-363 target genes RGS17 and HIPK3 both have been associated 
with drug response. 
These studies provide new information about genomic changes involved in 
progression and resistance to treatment in various types of cancer, and also highlight the 
power of applying genomic-wide array screening techniques in malignancies. The novel 
findings in these studies may serve as a useful resource for future studies and aid in 
development of novel therapeutic targets to increase the survival rates of cancer patients. 
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INTRODUCTION 
A recently discovered class of small RNA is microRNA with 20 to 24 nucleotides. MiRNAs 
are managers of gene expression and negatively regulate mRNA expression at the 
translational stage. They play a fundamental role in many cellular processes such as 
proliferation, apoptosis, survival, and tumorigenesis that impact on major biological systems 
such as cancer, and they have provided many new insights into cancer research (Mirnezami et 
al. 2009; Slaby et al. 2009). 
The first evidence of a connection between miRNA and human cancers came 
from findings in chronic lymphocytic leukemia. Further, more than 50% of miRNA genes are 
located within regions of loss of heterozygosity, amplification, fragile sites, viral integration 
sites, and other cancer-related genomic regions (Mirnezami et al. 2009). MiRNAs are 
involved in the initiation, progression, and metastasis of human cancer (Calin and Croce 
2006; Di Leva et al. 2006), and miRNA signatures that are related to diagnosis, staging, 
progression, and response to treatment are identifiable in human cancers (Setoyama et al. 
2011). However, those miRNAs which can be associated with progression and response to 
treatment in many cancers remain unknown. 
The microarray is one of the recent techniques that provide the possibility of 
profiling numerous miRNAs simultaneously in an experiment. With the microarray, miRNA 
profiling can reveal altered miRNAs, and novel alterations may serve as putative cancer 
markers which may aid in our understanding of molecular mechanisms underlying 
progression or those which are treatment-resistant. 
This thesis is concentrated on miRNA profiling of four different cancers: 
colorectal cancer (CRC), giant cell tumor of bone (GCTB), acute lymphoblastic leukemia 
(ALL), and acute myeloid leukemia (AML), by use of an miRNA microarray. The main 
purpose is to improve knowledge of miRNAs involved in tumor progression and drug 
resistance that might open up new therapeutic applications. 
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REVIEW OF THE LITERATURE 
 
1. Non-coding RNAs 
 
A simple formula regarding biological information until recently was that DNA is transcribed 
into mRNA, and mRNA is translated into protein. Recent discoveries have, however, 
revealed a new subtype of non-coding RNAs (ncRNAs) such as small ncRNAs (less than 200 
nucleotides) that subvert this formula by regulation of the transcription and translation of 
protein-coding RNAs (Figures 1A, and B) (Bernardao et al. 2012). These small RNAs 
include small interfering RNAs (siRNA), small nucleolar RNAs (snoRNA), small nuclear 
RNAs (snRNA), piwi-interacting RNA (piRNA), and microRNAs (miRNA) (Figure 1C). 
Another subtype of ncRNA comprises long ncRNAs, endogenous cellular RNAs of more 
than 200 nucleotides in length that have no open reading frame of significant length (<100 
amino acids). Long ncRNAs act in different ways in the cell; for instance, they regulate gene 
expression and influence protein localization (Gutschner and Diederichs 2012). 
 
2. MiRNAs 
 
The first ncRNA, miRNA, was discovered in in the Ambros and Ruvkun labs in 1993 when a 
gene, lin-4, crucial for nematode Caernohabditis elegans development, was found to not 
encode a protein but to give rise to a small 22-nucleotide RNA. The RNA itself was 
responsible for silencing the lin-14 gene, via antisense complementarity to its 3’ untranslated 
region (UTR) (Lee et al. 1993; Wightman et al. 1993). The second important miRNA was 
identified also in the nematode Caernohabditi elegans in 2000 which was let-7 (Reinhart et 
al. 2000). Let-7 was identified soon in human beings and in animals, as well (Pasquinelli et 
al. 2000; Basyuk et al. 2003). Subsequently, hundreds of miRNAs and their biological 
functions have been identified, and thus far (August 2012) 25,141 mature miRNAs in 193 
species, including 2,042 mature human miRNAs, have been registered in the miRBase data 
base (http://microrna.sanger.ac.uk) (Ambros 2001; Vandenboom Ii et al. 2008). MiRNAs 
play the vital roles in basic biological functions such as growth, invasion, angiogenesis, 
proliferation, and differentiation via the negative regulation of over one-third of all human 
genes at the translational stage (Bartel 2004; Lee et al. 1993). The miRNAs may have either 
an oncogenic or a tumor-suppressive function (Croce 2009). MicroRNA genes represent 1 to 
3% of the currently known genes in the human genome (Bartel 2004). Although the miRNA 
  
13 
 
genes are located in either introns or exons of protein-coding genes, a larger number of 
miRNA genes are found in intron regions (Negrini et al. 2009).  
 
 
 
 
 
 
 
Figure 1. Molecular biology. (A) Schematic overview of molecular biology before and (B) after discovery of 
non-coding RNA transcripts. (C) RNA family. (Figure 1(A) & (B) are reprinted from Heart, Lung and 
Circulation, Vol. 21(3), Bernardo BC, et al. A microRNA guide for clinicians and basic scientists: background 
and experimental techniques, pp. 131-142, Copyright (2012), with permission from Elsevier. Figure 1 (C) has 
been modified from Buckingham S., 2003). 
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2.1. MiRNA biology 
 
The miRNA genes are initially transcribed in the nucleus and are called primary miRNAs 
(pri-miRNAs) (>1000 bases) which contain multiple stem loop/hairpin structures. The 
enzyme Drosha then cleaves pri-miRNAs into precursors (pre-miRNAs) with 60 to 100 
nucleotides. The pre-miRNAs are transported to cytoplasm by Exportin 5 and cleaved by 
Dicer to form an miRNA: miRNA* duplex about 15 to 22 nucleotides in length. This duplex 
then unwinds into mature miRNA and passenger miRNA (miRNA*). Recently, deep 
sequencing data have shown that some miRNAs* are not degraded; they even play a 
functional role in the regulation of miRNA homeostasis and exert downstream effects on 
transcription and translation of RNA and DNA (Suzuki and Miyazono 2011). The mature 
RNA is incorporated into an RNA-induced silencing complex (RISC) where it binds to a 
complementary sequence in the 3’UTR of target mRNA. The mechanism of inhibition of 
translation depends on the degree of miRNA-mRNA complementarity (imperfect or perfect) 
that results in inhibition of protein synthesis or mRNA degradation (Figure 2) (Bernardo et al. 
2012). 
 
 
Figure 2. Biogenesis of microRNA. Reprinted from Heart, Lung and Circulation, Vol. 21(3), Bernardo BC, et 
al. A microRNA guide for clinicians and basic scientists: background and experimental techniques, pp. 131-142, 
Copyright (2012), with permission from Elsevier. 
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2.2. MiRNAs in human diseases 
 
Since the year 2000, over 2000 studies have been conducted regarding miRNAs (Figure 3A) 
(van Rooij et al. 2012) and their correlations with various diseases such as cancers, 
cardiovascular disease, schizophrenia, renal function disorders, psoriasis, primary muscular 
disorders, Fragile-X mental retardation syndrome, diabetes, chronic hepatitis, AIDS, and 
obesity (http://cmbi.bjmu.edu.cn/hmdd) (Figure 3B).  
 
 
 
Figure 3.  (A) Number of yearly published patent applications and issued patent associated with miRNAs and 
their applications in US and Europe. (B) State of distribution of miRNAs’ documents in medicinal preparations. 
Reprinted from Circulation Research, Vol. 110(3), van Rooij E., et al. Developing microRNA therapeutics, pp. 
496-507, copyright (2012), with permission from Wolters Kluwer Health 
 
2.3. MiRNA in cancer 
 
The first investigation that indicated the relation between miRNA and human cancers was in 
2000. This study found miR-15 and miR-16-1 in the most commonly deleted region, 13q14, 
in CLL; subsequently, their frequent deletion or down-regulation has been detected in the 
majority of CLL cases (Calin et al. 2002). MiR-15 and miR-16-1 function as tumor 
suppressors, and their expression inversely correlates with anti-apoptotic BCL2 expression 
where inhibition of BCL2 by miR-15 and miR-16-1 enhance apoptosis in leukemic cells. 
Thus, somatic deletion of miR-15 and miR-16-1 facilitates leukaemogenesis as bypass 
apoptosis (Cimmino et al. 2005). 
Another early finding that indicates a link between miRNA and cancer 
formation is the detection of over 50% of miRNA genes in regions of loss of heterozygosity, 
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amplification, fragile sites, viral integration sites, and other cancer-associated genomic 
regions (Calin et al. 2004; Mirnezami et al. 2009). Deregulation of miRNA expression has 
been evident in various types of cancers including colorectal cancer and in leukemia, lung, 
and breast cancers. MiRNA profiling compared to mRNA expression profiling seems to be a 
more accurate method of classifying tumor subtypes (Lu et al. 2005).  
MiRNAs can function as either oncogene- or tumor-suppressors. Over-
expression of oncogenic miRNAs and under-expression of tumor-suppressive miRNAs can 
contribute to tumorgenesis by affecting pathways promoting acquisition of the hallmarks of 
cancer. These hallmarks include sustaining proliferative signaling, resisting cell death, 
evading growth suppressors, inducing angiogenesis, enabling replicative immortality, and 
activating invasion and metastasis (Hanahan and Weinberg 2000). 
 
2.4. MiRNAs as prognostic markers 
 
Prognostic markers provide informaion on the likely course of cancer disease in an untreated 
individual that are objectively measurable (Italiano 2011). The possible applications of 
miRNAs not only in molecular diagnostics but also in molecular prognostics, particularly in 
cancer, are provided by discovery of the role of miRNA in numerous pathological processes, 
and for cancer prognosis, miRNA can be complementary to other genomic and proteomic 
biomarkers (Cho 2007).  
The role of miRNA in prediction of outcome and prognosis is evident in several 
cancer studies. In pancreatic cancer, over-expressed miR-21 correlates with the presence of 
liver metastasis, and with the Ki67 proliferation index that suggests changes in miRNA 
expression as being associated with cancer progression (Roldo et al. 2006). Family members 
of let-7 and miR-155 were identified as related to survival, and a lower level of let-7 and a 
higher level of miR-155 correlate with poor post-operative survival in lung cancer 
(Takamizawa et al. 2004; Yanaihara et al. 2006). Over-expression of miR-155, which also 
associates with the poor-prognosis phenotype in B cell lymphomas, suggests a general 
predictor role for miR-155 in aggressive tumor phenotypes (Calin et al. 2005; Mirnezami et 
al. 2009). 
Expression of miR-200c is associated with overall survival after surgery in 
colorectal cancer (Xi et al. 2006). In CLL, miRNA profiling independently predicts the 
prognosis of disease and expression of poor prognostic markers such as ZAP-70 and status of 
the immunoglobulin variable-region heavy-chain gene. Thirteen miRNAs discriminate 
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between patients with good and poor prognosis. Two of these are miR-16-1 and miR-15a, 
which show lower levels in patients with good prognosis. According to reports, loss at 
13q14.3, harboring these genes, is a favorable prognostic feature (Calin et al. 2005). 
 
2.5. MiRNA as predictive markers 
 
Predictive biomarkers provide information on likely benefit from a particular treatment type 
(Italiano 2011). Despite significant advances in cancer therapy, drug resistance is still a major 
obstacle in its treatment. Thus, better understanding of mechanisms underlying drug 
resistance is needed to improve treatment results. The main mechanisms of resistance are as 
follows: 1) altered expression of the ATP-binding cassette family of transporters on cell 
membrane transporters, 2) alterations in DNA repair pathways, 3) resistance to apoptosis, and 
4) target modifications (Rodrigues et al. 2012). Recent studies have indicated an emerging 
role for miRNAs, in addition to genetic and epigenetic changes (methylation/acetylation), in 
the anticancer-drug-resistant phenotype (Giovannetti et al. 2012), which opens up the 
possible application of miRNAs in evaluation of outcome and modification of response in 
known anti-tumor therapies (Hummel et al. 2010). MiRNA can change cellular response to a 
specific drug or class of drugs not only through survival or apoptotic signaling but also by 
interfering with drug targets and DNA repair (Giovannetti et al. 2012). To restore drug 
sensitivity via miRNAs, potential approaches include activation of tumor suppressor miRNAs 
or inactivation of oncogenic miRNAs and modulation of miRNA target genes, oncogenes, 
and tumor suppressor genes, through up- or down-regulation of miRNAs (Sarkar et al. 2010; 
Giovannetti et al. 2012). For example, Miller et al. (2008) found significant up-regulation of 
eight miRNAs and down-regulation of seven miRNAs in a tamoxifen-resistant cell line, 
relative to a sensitive cell line. 
Another study on breast cancer reveals that miR-451 regulates multi-drug-
resistance 1 (mdr1) which is an important factor in drug resistance. A set of differentially 
expressed miRNAs also exists in a multi-drug-resistant human gastric-cancer cell line 
(Kovalchuk et al. 2008). Up-regulation of miR-214 causes increased resistance to cisplatin in 
ovarian cancer (Yang et al. 2008). Furthermore, the crucial role of miRNAs also has been 
demonstrated in drug resistance in other types of cancers such as prostate and non-small cell 
lung cancers (Fujita et al. 2008; Garofalo et al. 2008).  
 Altogether, recent evidence suggests that a drug-resistant-associated miRNA 
signature could serve for stratifying patients and choosing treatment options that most likely 
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will show successful results for a particular individual. In addition, this aids in discovery of 
new drugs and biomarkers that may enhance management and outcome in patients with 
cancer (Gorenchtein et al. 2012).  
 
3. MiRNA detection 
 
To investigate the cellular roles of miRNAs, a key approach is to profile the mature miRNAs 
in specific tissue types at various disease stages (Wark et al. 2008). Considerable effort has 
been devoted to developing new methods for high-throughput detection of miRNAs. A time 
line for miRNA discovery and detection is in Figure 4 (Wark et al. 2008). For several 
reasons, however, detection of miRNAs is technically challenging. Due to the short length of 
mature miRNAs, very little sequence is available to design complementary microarray and 
perform reliable amplification or labeling of each miRNA without introducing signal bias. 
MiRNAs show sequence similarity in the same family, and only one nucleotide can 
differentiate them from each other. As the target sequence is present in both pri- and pre-
miRNAs, it is also important to make certain that they do not contribute to the array detection 
signal (Wark et al. 2008; Bernardo et al. 2012).  
 
3.1. Microarray and deep sequencing 
 
The miRNA microarray is one of the recent techniques that allow profiling of numerous 
miRNAs (~1000 miRNAs) simultaneously, while requiring only small amounts of total 
miRNAs. The relative expression level of miRNA is detectable by microarray. In brief, the 
sample’s dephosphorylation and direct-labeling take place in the same tube. Then, 
hybridization occurs between RNA samples and microarrays containing probes for each 
identified miRNA from the Sanger miRBASE public database. Agilent’s SurePrint inkjet 
technology synthesizes 40- to 60-mer oligonucleotide probes directly on the array, and this 
leads to high-purity, high-fidelity probes. The Agilent miRNA microarray probe is 
represented in Figure 5A. Agilent’s microarray contains ~15,000 features printed in an 8-plex 
format. Probe design requires prior sequence information; this is a limitation of microarrays 
(Bernardo et al. 2012). Capture probes are in one of two forms, synthetic oligonucleotides or 
cDNA fragments (Yin et al. 2008). In addition, exogenous and endogenous positive and 
negative control probes are essential to aid normalization and provide absolute reference 
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points for quality control and quantitative comparison of different microarrays (Yin et al. 
2008). For a schematic overview of miRNA microarray see Figure 5B.  
Recently, next-generation sequencing has overcome some of the microarray 
limitations. The advantages of this technique are as follows: 1) having prior sequence 
information is unnecessary, 2) information about all RNA classes is supplied by this method, 
and 3) it provides the possibility to discover novel miRNAs or other types of small RNAs. 
The limitation is the size of the data output, which is large and complex, hence requiring 
extensive computational power, data storage, bioinformatics analysis for interpretation of 
data, and further functional analysis to test the data (Bernardo et al. 2012). 
The validation of data obtained by microarray or deep sequencing is essential with 
quantitative real time PCR, Northern blotting, or in situ hybridization (Bernardo et al. 2012). 
 
 
 
Figure 4. Discovery and detection of miRNA during the time. Reprinted from Angewandte Chemie 
International Edition,Vol. 47(4), Wark AW., et al, Multiplexed detection methods for profiling microRNA 
expression in biological samples, pp. 644-652, copyright (2008), with permission from John Wiley and Sons. 
 
 
3.2. Quantitative real time PCR (qRT-PCR) 
 
The most-used method to verify data from genome-wide expression profiling is qRT-PCR. 
Two different approaches allow detection of specific miRNAs by qRT-PCR; one utilizes 
miRNA-specific reverse transcription primers and initially uses stem–loop miRNA-specific 
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primers, and another adds a common sequence (poly(A) tail) to the 3′-end of all miRNAs and 
utilizes universal reverse transcription primers (Bernardo et al. 2012). Among the number of 
existing fluorescent-based technologies for qPCR, only SYBR Green and TaqMan® have 
successfully served to detect miRNA. It is also important to normalize miRNA expression by 
use of suitable reference or housekeeper gene following qPCR (Bernardo et al. 2012). 
 
3.3. Northern blotting 
 
One of the earliest methods to detect single miRNA molecules directly is northern blotting, 
without any need for chemical or enzymatic modification of the target molecules prior to 
analysis (Wark et al. 2008). Compared to array and qRT-PCR, this method has the advantage 
of detection of both miRNA and pre-miRNA. However, because of small size and low 
abundance of miRNA molecules, northern blotting can be technically challenging. This 
method also is time consuming, and requiring a large amount of RNA (10-15µg) (Bernardo et 
al. 2012). This method is described by Varallyay et al. (2008). 
 
3.4. MiRNA in situ hybridization 
 
For visualization and localization of genes in a cell or in tissue, in situ hybridization is the 
method most commonly used. Since the stringency and specificity of this method decrease 
with shortening of the probes, its use in miRNA detection is limited. Conventional in situ 
hybridization works for highly expressed miRNAs, but it shows inconsistent or negative 
results for ones with low expression (Bernardo et al. 2012). 
 
3.5. MiRNA in formalin-fixed and paraffin-embedded (FFPE) samples 
 
FFPE tissue is a widely used archive material for biomarker discovery and validation (Lewis 
et al. 2001). These types of samples represent a challenge for mRNA profiling due to RNA 
degradation during fixation (Macabeo-Ong et al. 2002), and storage (Cronin et al. 2004). In 
contrast, due to their stability and small size, miRNAs are better preserved, and their RNA 
can be readily extracted from FFPE samples (Hui et al. 2009). This therefore greatly 
enhances our ability to assess miRNAs as cancer biomarkers. In addition, the reliability of 
bone marrow core biopsies, which undergo decalcification besides the formalin fixation, has 
been studied for miRNA profiling, because decalcification also influences the integrity of 
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nucleic acids, especially RNA, and results have confirmed that use of core biopsies is feasible 
for miRNA profiling (Borze et al. 2011).   
 
 
 
  
 
 Figure 5. (A) MiRNA probe. (B) Schematic overview of miRNA microarray. 
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4. MiRNA target genes 
 
MicroRNAs cover 1 to 3% of the genomes and regulate 30% of all human genes, and each 
miRNA regulates up to several hundred target genes; each target gene may also be regulated 
by multiple miRNAs (Bartel 2004; Lewis et al. 2005). Several databases are available to 
predict the miRNA target genes (Table 1). Each database has its own defined criteria based 
on combination of target features such as seed sequence matching and the evolutionary 
conversation of 3’ UTR sequences of candidate genes (Takada and Asahara 2012). For this 
reason, these databases often create different gene target lists. However, combination use of 
multiple databases reduces false positivity, and the results can be more specific (Bernardo et 
al. 2012). 
 
Table 1. Databases for prediction of miRNA target genes 
Data base  Web address 
miRBase  http://microrna.sanger.ac.uk 
TargetScan http://www.targetscan.org 
miRanda www.microRNA.org 
mirTarget2 http://mirdb.org/miRDB 
Tarbase http://diana.cslab.ece.ntua.gr/tarbase 
PICTAR  http://pictar.mdc-berlin.de/ 
    
 
4.1. Verification of targets 
 
Despite the power of computational databases to predict miRNA target genes, however, 
verification of target genes is essential, because interaction between miRNA and the target is 
complex, with poor overlap between databases (Bernardo et al. 2012). Reporter assay is one 
method for verification of the target of miRNA, because alteration in luciferase expression 
indicates whether a miRNA can bind to a target mRNA. Using miRNA mimics and 
inhibitors, and then measuring predicted targets of miRNAs by qPCR and Western blotting is 
another method, but one less direct. 
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5. Survey of neoplasia studied in this thesis 
Four different types of neoplasia, colorectal cancer (CRC), giant cell tumor of bone (GCTB), 
acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML), were studied here 
because identification of their prognostic and predictive biomarkers still is crucial. On the 
other hand, these cancers have been studied for years in our labrotary in collaboration with 
clinicians and physicians who can provide to us materials and relevant clinical data. 
5.1. Colorectal cancer (CRC) 
5.1.1. Clinical characteristics and treatment of colorectal cancer 
 
CRC is a disease arising in the epithelial cells lining the colon or rectum of the 
gastrointestinal tract. Overall annual detection of CRC is over one million cases, which in-
clude 9.4% of all cancer diagnoses, and it is the fourth deadliest cancer worldwide (Courtney 
et al. 2012). Both rates of incidence and death increase with age. Overall, 90% of new cases 
and 94% of deaths occur among persons aged 50 and older. CRC incidence is more common 
in men (American Cancer Society, 2011). In Finland, CRC is the third most common cancer 
type, and its incidence is about 2700 new cases annually (www.cancer.fi/). CRC at an early 
stage has often no symptoms. The symptoms and signs depend on tumor site. In general, 
symptoms include rectal bleeding and anemia which are sometimes associated with weight 
loss and changes in bowel habits. The signs of CRC are as follows: worsening constipation, 
blood in the stool, weight loss, fever, loss of appetite, and nausea or vomiting. 
Several factors related to increasing or decreasing risk for CRC are divided into 
modifiable and non-modifiable risk factors. Non-modifiable risk factors include personal or 
family history of CRC or adenomatous polyps, and a personal history of chronic 
inflammatory bowel disease. Environmental factors (physical inactivity, obesity, high 
consumption of red or processed meats, smoking, moderate-to-heavy alcohol consumption) 
are known as modifiable risk factors (American Cancer Society, 2011). However, 
environmental factors are suggested as the risk factor series which play a major role in the 
etiology of this disease (Boyle and Leon 2002). CRC cases most commonly present 
sporadically, with family history of CRC in 25% of patients (Migliore et al. 2011). On the 
other hand, inherited mutations in major CRC genes occur in 5 to 6% and in the rest of the 
familial forms, gene-environment interactions lead to disease (Jasperson et al. 2010). Some 
inherited conditions which predispose an individual to development of colorectal cancer are 
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familial adenomatous polyposis (FAP), attenuated FAP (AFAP), MUTYH-associated 
polyposis (MAP), and Lynch syndrome (hereditary nonpolyposis colorectal cancer); rare 
syndromes include hamartomatous polyposis conditions (Peutz-Jeghers syndrome, juvenile 
polyposis syndrome, and others) and hyperplastic polyposis (Aaltonen et al. 1993; Hemminki 
et al. 1997; Migliore et al. 2011).  
Human colon carcinogenesis progresses by dysplasia/adenoma to carcinoma. 
Stages are defined according to a tumor-node-metastasis (TNM) classification, as defined by 
the American Joint Committee on Cancer (AJCC) (Wolpin and Mayer 2008). The TNM 
definition is based on three variables: size and extent of the primary tumor (T), nodal 
involvement (N), and presence or absence of metastases (M). The individual T, N, and M 
variables are then combined into a grouped TNM stage, ranging from I to IV (Table 2) 
(Walters et al. 2012). Another system for classifiying tumors of the digestive system is based 
on the WHO classification which is used in Finland. TNM staging has nowadays replaced 
Duke´s classification or its Astler-Coller modification in which classifications the staging is 
based on the evaluation of the depth of invasion in the bowel wall and presence or absence of 
metastases. In Duke´s stage A, the growth is confined to mucosa, in stage B, the growth 
extends into the muscularis and serosa, in stage C it has spread to regional lymph nodes, and 
in stage D, distant metastases occur (Labianca et al. 2010). 
CRC treatment commonly is based on surgery, radiation, and chemotherapy. 
Moreover, two targeted monoclonal antibody therapies directed against the extracellular of 
EGFR (cetuximab, and panitumumab) have been approved by the US Food and Drug 
Administration (FDA) to treat metastatic CRC by inhibiting the function of this 
transmembrane. EGFR interacts with signaling pathways affecting cellular growth, 
proliferation, and programmed cell death. EGFR is overexpressed in up to 80% of CRC. 
Autonomous activation of EGFR can occur through mutation or amplification. EGFR 
mutation, however, is very rare, in CRC but over-expression of EGFR through amplification 
or increased copy number is detectable in 10 to15% of CRC (Shia et al. 2005). Anti-EGFR 
monoclonal antibodies have shown efficacy in 10 to 20% of mCRC (Wolpin and Mayer 2008). 
In addition to KRAS mutation, other genetic alterations may also be predictive biomarkers of 
response to EGFR-targeted monoclonal antibodies such as over-expression of EGFR ligands 
(amphiregulin and epiregulin), BRAF and PIK3CA mutations, and loss of PTEN (Heinemann 
et al. 2013). Data suggest that combination of wild-type KRAS, BRAF, and PIK3CA and 
expression of PTEN protein in patients leads to the best response to cetuximab and 
panitumumab (Merla and Goel 2012). Among them, the KRAS mutation is a major predictive 
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marker and the only one with its status determined in clinical practice before the start of 
treatment with anti-EGFR monoclonal antibodies based on a recommendation of the 
European Medicines Agency and the Food and Drug Administration (Lievre et al., 2010 In 
Finland, patients who are potential candidates for anti-EGFR monoclonal antibody treatment 
for metastatic disease all have their KRAS status checked before treatment initiation. BRAF 
mutations occur in 10 to 15% of CRC; they serve, however, better as aprognostic marker than 
as a predictive marker (Merla and Goel 2012). 
Resistance to an anti-cancer drug is the major hurdle for the success of 
chemotherapy (Longley et al. 2006). Recent studies have demonstrated the impact of 
miRNAs on the response of CRC cells to chemotherapeutic drugs. Over-expression of miR-
192 in CRC cells and of miR-22 in TP53-mutated CRC cells leads to increased 
chemosensitivity to methotrexate and to paclitaxel, respectively (Song and Ju 2010; Li et al. 
2011). The mechanism of anticancer activity of paclitaxel is via arresting microtubular 
polymerization and inducing apoptosis in cancer cells via binding to and inhibiting an 
apoptosis-stopping protein called Bcl-2 (Li et al. 2011).  
In CRC cell lines, over-expression of miR-143 also causes increased 
chemosensitivity to 5-fluorouracil (Borralho et al. 2009). The inhibition of miR-31 in CRC 
cells results in increasing chemosensitivity to 5-fluorouracil (Wang et al. 2010). On the other 
hand, over-expression of miR-215 reduces chemosensitivity to methotrexate and tomudex 
(Song and Ju 2010), with a lower level of miR-34a in 5-fluorouracil-resistant DLD-1 CRC 
cells than in parental cells (Zhai and Ju 2011). Methotrexate and tomudex are inhibitors of 
dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS, TS), respectively. DHFR 
and TS have been the main anti-cancer targets for the last 50 years, because of their critical 
functions (Song et al. 2010). The basis of systemic treatment for CRC is fluorouracil, a 
fluorinated pyrimidine that functions principally via inhibition of thymidylate synthetase, the 
rate-limiting enzyme in pyrimidine nucleotide synthesis (Wolpin et al. 2008). 
Treatment choices for CRC are based on stage and site of the tumor, as well as 
risks and advantages and vary from one patient to another. Survival is directly related to 
detection and the type of cancer involved, but overall is poor for symptomatic cancers, as 
they are typically quite advanced (Elizabeth et al. 2008). 
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Table 2. TNM classification (American Joint Commission on Cancer) 
Stage T N M  
I T1 N0 M0  
T2 N0 M0  
II T3 N0 M0  
T4 N0 M0  
III T1, T2 N1 or N2 M0  
T3, T4  N1 or N2 M0  
  IV Any T Any N M1  
T=size and extent of the primary tumor, N=nodal involvement, M=presence or absence of 
metastases.T1=Tumor invades submucosa, T2=Tumor invades muscularis propria, T3=Tumor 
invades through the muscularis propria into pericolorectal tissues, T4= Tumor directly invades other 
organs or structures and/or perforates visceral peritoneum, N0= No regional lymph node metastasis, 
N1= Metastases in 1–3 regional lymph nodes, N2= Metastases in 4 or more regional lymph nodes, 
M0= No distant metastasis, M1=distant metastasis 
 
 
5.1.2. Genetic alterations in colorectal cancer 
 
The process of carcinogenesis of CRC is multistep (from normal epithelium to metastasis) 
with involvement of an accumulation of mutations in tumor suppressor genes and oncogenes 
(Figure 6). A number of genes and cytogenetic changes are associated with either increased 
or decreased risk for CRC. Several loci identified by genome-wide association studies as 
possible common low-risk susceptibility alleles are polymorphisms at 8q23.3, 8q24, 10p14, 
11q23, 15q13, 14q22.2, 16q22.1, 18q21, 19q13.1, and 20p12.3 (Migliore et al. 2011). 
Polymorphisms of GSTT1, GSTM1, COX2, MTHFR, NATs, MTR, SMAD7, APC, and IGF1 
associate with increased risk for CRC (Migliore et al. 2011). 
The inactivation of the tumor suppressor gene APC and activation of the 
oncogene KRAS are the among earliest trigger genetic events (Bellacosa 2003). The KRAS 
mutation is detectable in over 40% of CRCs. The RAS signaling affects various cellular 
functions such as cell proliferation, growth differentiation, cell survival, apoptosis, 
cytoskeleton organization and function, inflammation, and cell transformation.  
Loss of function of SMAD2,4, and TP53 are indications of malignant 
transformation (Bellacosa 2003). Mutation of TP53 is found in 29% of all CRCs, with higher 
frequency in advanced-stage tumors and in tumors with poor prognostic features (Migliore et 
al. 2011). The frequency of TP53 mutation in CRC cases, however, based on WHO 2010, is 
70% (Bosman et al. 2010).  
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The achievement of genomic instability is a key hallmark of CRC which is 
classified into three subtypes: microsatellite instability (MSI), chromosomal instability (CIN), 
and the CpG island methylator phenotype (CIMP) (Migliore et al. 2011).  
The first report of MSI was in 1993 as the presence of thousands of somatic 
alterations in the length of DNA in sporadic (Ionov et al. 1993; Thibodeau et al. 1993) and 
familial CRC (Aaltonen et al. 1993). There are at least 500,000 microsatellites in the human 
genome (de la Chapelle and Hampel 2010). MSI is detectable in 15 to 20% of sporadic CRC 
and is due to a loss of DNA mismatch repair function, secondary to inactivation of MMR 
genes (Migliore et al. 2011). The most common mechanism of MMR inactivation is via an 
acquired methylation of the hMLH1 gene promoter (Goel et al. 2007). In monomorphic 
microsatellites the same number of repeat units is shared in all individual and in polymorphic 
microsatellites, a varied number of repeats among individuals is shared (de la Chapelle and 
Hampel 2010). 
In 80 to 85% of CRCs, CIN is the most common type of genomic instability and 
is characterized mainly by chromosomal rearrangements and numerical abnormalities 
(Migliore et al. 2011). The most frequent aberration detectable by CGH in primary CRC 
involved gains at 3/3q, 5/5p/5q, 7, 8q, 20/20q, 13, and the X, and losses at 8p and 18/18q 
(Migliore et al. 2011). However, cytogenetic changes at 18q (including tumor suppressor 
genes SMAD4/DPC4) is the most recurrent aberration which is found by all studies in either 
primary tumors or in colon cancer cell lines or in fixed colorectal cancer tissue blocks 
(Migliore et al. 2011). Both microsatellite instability and loss of heterozygosity at 18q are 
identifiable prognostic markers (Lurje et al. 2007; Migliore et al. 2011). In the first published 
paper regarding dysregulated miRNAs in CRC, down-regulation of miR-145 and miR-143 in 
CRC compared to that in the normal controls was reported in 2003 (Michael et al. 2003). 
Subsequently, several studies have focused on miRNA profiling in either CRC cell lines or 
tumor samples in which numerous miRNAs are consistently dysregulated (Table 3) (Zhai and 
Ju 2011).  
A number of miRNAs have been described as related to epithelial–
mesenchymal transition (EMT), an evolutionarily conserved developmental process (Table 
4). The miRNAs, detected as diagnostic markers in plasma or stool samples from CRC 
patients, are presented in Table 4. Moreover, the great potential of miRNAs as prognostic 
biomarkers is identified for CRC (Table 4), with miR-200c as the first reported miRNA 
related to colon cancer prognosis (Zhai and Ju 2011).  
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Table 3. Common miRNAs deregulated in CRC  
Regulation miRNA 
over-expressed miR-20,miR-21,miR-31, miR-99b 
under-expressed miR-143,miR-145, miR-192 
Data based on Zhai & Ju (2011) 
 
 
Table 4. The miRNAs identified related to metastasis, diagnosis, and prognosis of CRC 
 Category miRNA 
miRNAs associated with EMT 
miR-200 family, miR-192, miR-215, miR-194,  
miR-21, miR-31, miR-9, miR-335 
miRNAs as diagnostic markers   miR-106a, miR-141, miR-17-3p, miR-21,  
miR-29a, miR-92  
miRNAs as prognostic markers  miR-106a, miR-141, miR-143, miR-200c,  
miR-21, miR-215, Let-7 and LIN28B 
Data based on Zhai & Ju (2011) 
 
 
 
Figure 6. Pathways, target genes and miRNAs involved in carcinogenesis of CRC. Reprinted from Molecular 
Cancer, Vol. 8,  Slaby O et al., the MicroRNAs in colorectal cancer: translation of molecular biology into 
clinical application, pp. 102, Copyright (2009), under the terms of Creative Commons Attribution License. 
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5.2. Giant cell tumor of bone (GCTB) 
 
5.2.1. Clinical characteristics and treatment of giant cell tumor of bone 
 
GCTB is a benign tumor of the skeleton that is locally aggressive and may rarely undergo 
malignant transformation into giant cell rich sarcoma and metastazise (McDonald et al. 1986; 
Katz et al. 1987; Fletcher et al. 2013). GCTB represents 4 to 5% of all primary bone tumors 
and 20% of all benign primary bone tumors (Fletcher et al. 2013). The incidence varies 
among races; for instance, its incidence is up to 20% of all primary bone tumors in China 
(Sung et al. 1982). The range of local relapse in patients is from 34 to 50%, and up to 6% of 
GCTB cases experience metastasis which occurs exclusively in the lung (McDonald et al. 
1986; Katz et al. 1987). This disease occurs in adults at ages 20 to 45.   
GCTB is characterized by a distinctive, multinucleated osteoclast-like 
population (Figure 7). Giant cells are not regarded as neoplastic, and the mononuclear cells of 
the tumor form the neoplastic tumor population. In addition to GCTB, infiltration of giant cell 
is obvious in various type of diseases such as aneurysmal bone cysts, chondroblastoma, giant 
cell-rich sarcomas and carcinomas, and primary giant cell sarcomas of bone (Domovitov and 
Healey 2010; Won et al. 2011). In GCTBs, involvement of the ends of long bones is 
predominant, around the knee (distal femur, proximal tibia) and wrist (distal radius) (Turcotte 
2006). The most common symptoms are pain and deformity at the disease site with increased 
risk for fracture (Turcotte 2006). According to the Enneking staging system, GCTB patients 
are classified into three stages. Tumors are limited to bone in stage I and extend into the 
surrounding soft tissue in stage 3 (Enneking 1986). The patients’ radiographic grading is 
from 1 to 3 according to the Campanacci system: grade I with well-defined margins of 
lesions and no penetration into the cortex, and grade III with irregular margins and cortical 
destruction (Campanacci et al. 1987).  
Rare familial syndromes are associated with giant cell-rich tumors. There is a 
familial clustering of Paget’s disease and GCTB (Rendina et al. 2004). 
The macroscopic appearance of GCTB is as a hemorrhagic soft mass that 
erodes bone. Microscopically, the tumor’s characterization is a minor stromal cell population 
and a second population of monocytes and eponymous multinucleated giant cells (Fletcher et 
al. 2002). The proteins expressed in GCTB are expressed by osteoclasts. 
The treatment option for resectable GCTB is surgery including curettage, en 
bloc resection, and amputation. The adjuvant therapies may reduce recurrence rate. Because 
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the heat of polymerization of methylmetharcrylate cement may sterilize the margins of 
surgery, risk for recurrence decreases after curettage (Klenke et al. 2011). En bloc resection is 
usually reserved for patients with stage III, and the recurrence rate is less than 20% 
(Campanacci et al. 1987). The site of the disease is clinically important, because the curative 
surgery of tumors which involve the sacrum, base of the skull, and the axial skeleton are 
accompanied by high intraoperative complication rates and by risk for incontinence and 
impotence (Thomas 2012). Radiotherapy is effective when surgery is contraindicated, such as 
by unacceptable morbidity or difficult achievement of adequate margins (Caudell et al. 2003). 
Control rates with only radiotherapy are 60 to 84%, and this may be less in pretreated patients 
or for recurrence (Caudell et al. 2003). Radiofrequency ablation and chemoembolization are 
other local ablative therapies (Santiago et al. 2009; Onishi et al. 2010). Chemotherapy serves 
usually for advanced GCTB, for symptomatic and progressive disease (Stewart et al. 1995; 
Faisham et al. 2006).    
Treatment of recurrent or unresectable GCTB with the fully human monoclonal 
antibody against RANKL called denosumab, which works by inhibiting osteoclast-mediated 
bone destruction, shows a positive response in approximately 90% of patients and reduced 
pain or improved functional status or both in about 85% of cases. This suggests that 
denosumab is a viable treatment option for advanced or metastatic GCTB cases not amenable 
to surgery (Beebe-Dimmer et al. 2009; Thomas et al. 2010).  
 
 
 
Figure 7. Histopathologic features of giant cell tumor of bone (GCTB). (A) GCTB cells with Hematoxylin-
eosin staining (20x). (B) Monocyte/macrophage marker stained, CD68 (20x). This picture was kindly provided 
by Dr. Helena Autio-Harmainen 
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5.2.2. Genetic alteration in giant cell tumor of bone 
 
Based on numerous investigations, size, anatomic site, radiological appearance, presence of 
pathological fractures, histological grading, and DNA content do not associate with rate of 
relapse and are not predictor markers for aggressive behavior or metastasis of the GCTB 
(Zheng et al. 1995). To identify predictors of the biological behavior of GCTB and prognostic 
indicators, several studies have therefore been conducted. 
  Over-expression of c-myc is found in most of GCTB samples which develop 
metastases. A highly significant correlation is observable between over-expression of c-myc 
and rate of metastasis (Gamberi et al. 1998). C-myc is involved in control of cell growth, 
differentiation, and apoptosis in various cell systems. Amplification or over-expression of the 
c-myc oncogene occurs also in various sarcomas and in Ewing’s and osteosarcoma cell lines 
(Barrios et al. 1993, 1994a, 1994b).  
An essential process for tumor growth and metastases is neoangiogenesis (Keck 
et al. 1989; Leung et al. 1989). On the other hand, production of VEGF is critical for the 
formation of the osteoclast (Niida et al. 1999). Evaluation of the expression level of VEGF in 
GCTB reveals its presence in spindle-shaped stromal-like tumor cells, round macrophage-like 
cells, and osteoclast-like multinucleate giant cells. A correlation exists between levels of 
VEGF expression and Enneking’s clinical stage of GCTB, with higher levels of VEGF gene 
expression at stage III than at stages I/II. An increase in vascular density correlates with a 
high occurrence of metastases and poor prognosis in numerous neoplasms. Thus, VEGF has 
prognostic value and may be associated with an advanced stage of GCTB (Zheng et al. 2000). 
Another study has shown, in addition to VEGF, a correlation between clinical stage of GCTB 
and expression level of MMP-9, with advanced stages showing a higher expression level of 
both VEGF and MMP-9 (Kumta et al. 2003). Their expression levels differ also between 
recurrent and stage II and III lesions; in recurrent lesions, their levels of expression are higher 
(Kumta et al. 2003). 
Amplified IL-6, u-PA, u-PAR, and PAI1 genes are apparent in GCTB, and the 
percentage of samples with these amplifications increases with metastases, thus suggesting a 
possible association of these factors with a higher biological aggressiveness of GCTB 
(Gamberi et al. 2004). Cytogenetic analysis of GCTB reveals a gain at the 20q11.1-
containing TPX2 gene in a series of relapsed samples, and TPX2 is proposed as a prognostic 
candidate oncogene (Smith et al. 2006). A correlation has been apparent between high 
expression of TNC and poor prognosis of GCTB. The over-expression of TNC is related to 
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risk for local recurrence and metastasis (Pazzaglia et al. 2010). Involvement of TNC in tumor 
growth, metastasis, angiogenesis, and in the inhibition of immunosurveillance is reported 
(Orend and Chiquet-Ehrismann 2006). In another study, mutation of p53, a tumor suppressor 
gene, is suggested as a prognostic marker (Papanastassiou et al. 2010).  
To identify predictive markers of aggressive behavior, it is useful to compare 
patients with and without developing lung metastasis. Results reveal higher frequency of 
thioredoxin peroxidase, allograft inflammatory factor 1, ubiquitin E2N, and glutathione 
peroxidase 1 over-expression in primary tumors of lung metastases or locally relapsed 
compared to frequency in a disease-free group (Conti et al. 2011). Moreover, Kaplan–Meier 
analysis shows a relation between high expression of glutathione peroxidase 1 and local 
recurrence and metastasis (Conti et al. 2011). The role of tumor suppressor gene RUNX3, 
which plays an important role in carcinogenesis and in the progression of malignancies, has 
been under study in GCTB, indicating that loss of RUNX3 may associate with carcinogenesis 
but not with aggravation (Han and Liang 2012). 
EGFR is implicated in bone remodeling (Zhu et al. 2007). Evaluation of the 
contribution of protein expression to aggressiveness and recurrence of GCTB demonstrates 
that EGFR expression is more frequent in recurrent than in non-recurrent cases, and in 
clinicoradiologically aggressive than in latent cases (Balla et al. 2011). 
  Despite numerous studies on GCTB, miRNAs and their role in GCTB 
progression still remain unstudied. Work on miRNAs may lead to identification of new 
biological markers to predict the tumor’s clinical behavior. 
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5.3. Leukemias 
 
In normal hematopoiesis, immature pluripotent hematopoietic stem cells (HSC) self-renew or 
differentiate into any of the mature blood cell lineages (Figure 8). In leukemia, the normal 
developmental program of the hematopoietic system is disordered, and malignant 
hematopoietic precursors accumulate (Izraeli 2004). The type of leukemia classification is 
based on the malignant cell lineage as being either myeloid or lymphoid. Additionally, some 
rarer leukemia types express no lineage-specific antigen and show a mixed phenotype of 
neoplastic cells. Leukemia is classified also into two types, chronic and acute, based on the 
maturity of the leukemic cells. In the chronic type, symptoms are mild, disease develops 
slowly, and the neoplastic cells are more mature; in the acute type, symptoms are more 
severe, disease develops rapidly, and the neoplastic cells are immature different types of 
progenitor forms. Some general features for leukemia are shared in common with other 
diseases, ones such as fatigue, malaise, abnormal bleeding, excessive bruising, weakness, 
weight loss, bone or joint pain, infection and fever, abdominal pain, and enlarged spleen, 
lymph nodes, and liver. Thus to confirm the diagnosis, several tests are essential.  
There are four main types of leukemia: ALL, AML, CLL and CML. The types studied in this 
thesis are ALL and AML, because in our laboratory, several studies have been conducted on 
these two types of cancer but not on the biological and clinical aspects of miRNAs. 
 
Figure 8. Normal hematopoiesis. MSC, Multipotent stem cell; CLP, Common lymphoid progenitor; CMP, 
Common myeloid progenitor; Pro-NK, Natural killer progenitor cell; Pro-T, T-cell progenitor cell; Pro-B, B-cell 
progenitor cell; MEP, Megakaryocyte erythroid precursor cell; GMP, Granulocyte macrophage precursor cell. 
Figure 8 has been modified from Wadhwa & Thorpe 2008. 
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5.3.1. Acute lymphoblastic leukemia (ALL)  
 
5.3.1.1. Clinical characteristics and treatment of acute lymphoblastic leukemia 
 
ALL is characterized by continuous multiplication of malignant and immature lymphoid 
cells. It is the most common malignant disease in children and includes 25% of all pediatric 
malignancies. Two peaks of incidence occur at ages 2 to 4 years (4-5/100 000) and at over 
age 50 (1/100 000) (Faderl et al. 2003). In Finland, the incidence of acute leukemias is 
approximately 240 new cases every year (Engholm et al. 2009, NORDCAN: cancer 
Incidence, Mortality, Prevalence and Prediction in the Nordic Countries, Version 3.5 
http://www.ancr.nu). 
Age and WBC count are prognostic indicators of outcome (Gustafsson et al. 
2000; Seibel et al. 2008). Children at ages 1 to 9 have a better outcome than do either infants 
or adolescents (Gustafsson et al. 2000). In B-cell precursor ALL, WBC>30x109/l is 
associated with poor prognosis and in T-ALL, WBC>100x109 raises the risk for relapse 
(Rowe et al. 2005).  
Pediatric ALL patients with B-cell precursor, ones aged 1 to 9 years with initial 
WBC<50x109/l, are categorized as a standard-risk group, and the rest of the patients as at 
high risk, according to the National Cancer Institute (Smith et al. 1996). Immunophenotype, 
cytogenetic abnormalities, and response to induction therapy are other commonly used 
factors (Smith et al. 1996). Risk classification has improved treatment results. Thus, refining 
of the risk classification by use of any new factors identified is necessary. Detection of the 
miRNAs involved may open new insight into the mechanism of ALL and also into 
classification of ALL risk groups. 
The treatment commonly used for ALL includes remission-induction, 
consolidation, and maintenance therapy (Faderl et al. 2003). The goal of treatment is 
restoration of normal hematopoiesis, prevention of drug-resistant subclones of blast cells, 
central nervous system (CNS) prophylaxis, and elimination of minimal residual disease via 
post-remission consolidation (Faderl et al. 2003). The treatment protocol for pediatric ALL 
has changed from national protocols to uniform protocols in Nordic countries during the 
1980s to 1992. Common Nordic protocols were established for all risk groups in 1992 
(Gustafsson et al. 1998). Since 1990, the Finnish Leukemia group has introduced in Finland 
three consecutive clinical trials (each trial including six treatment blocks and maintenance 
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therapy during three years). Regarding treatment for infants, a large international 
collaborative trial, Interfant-99, began in 22 countries in 1999 (Pieters et al. 2007). 
Although the outcome of childhood ALL has significantly improved, 25% of 
the patients still experience relapses. A considerable proportion, two-thirds of the failures, 
occurs among patients in standard risk or intermediate risk groups who have no unfavorable 
prognostic features at diagnosis (Gustafsson et al. 1998). Identification of new prognostic 
markers in ALL patients to refine more precisely risk groups is therefore necessary. 
However, both relapse and mortality due to treatment is higher in adults than in children. 
Poor outcome in adults is probably due to poorer treatment tolerance and changes in biology 
of the disease with age (Pui and Evans 2006). 
 
5.3.1.2. Genetic alteration in acute lymphoblastic leukemia 
 
Hyperdiploidy (>50 chromosomes), chromosomal number change, is common in pediatric 
ALL (25%) but rare in adults (Forestier et al. 2006). The outcome in pediatric ALL with 
hyperdiploidy is excellent, with event-free survival for 5 years being more than 80%. Gains 
in chromosomes X, 4, 6, 10, 14, 17, 18, and 21 are the most common alterations in the 
hyperdiploidy cases (Mertens et al. 1996). Hypodiploidy, however, is uncommon in all age 
groups and is related to very poor prognosis (Kantarjian et al. 2000). Chromosomal 
translocation is a characteristic feature in ALL. The most common translocation in a pediatric 
B-cell precursor, but rare in adults, is t(12;21)(p13;q22) that leads to formation of the ETV6-
RUNX1 (TEL-AML1). An association between this translocation and good prognosis has 
emerged (Rubnitz et al. 1997; Uckun et al. 2001; Jabber Al-Obaidi et al. 2002). In adults, B-
cell precursor ALL t(9;22)(q34;q11) is the most common translocation, resulting in formation 
of BCR-ABL fusion and the Philadelphia chromosome. This translocation is marker for poor 
prognosis in ALL, independent of age (Ribera et al. 2005). Two common forms of 
rearrangements of 11q23 involving MLL, ones occurring frequently in infant ALL, are 
t(4;11)(q21;q23) and t(11;19)(q23;p13) (Meyer et al. 2009). The prognosis is very poor in 
infants with MLL rearrangements and event-free survival, at about 45 to 50% (Pieters et al. 
2007).   
Despite some similarity in cytogenetic changes between B-cell precursor and T-
ALL, differences do exist. Those genes which are important in T-cell development are 
involved also in T-ALL. Over 30% of T-ALL cases have T-cell receptor gene rearrangements 
in 14q11, 7q34, and 7p14 (Cauwelier et al. 2006). In pediatric t(11;14)(p13;q11) and in adult 
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t(10;14)(q24;q11) translocating TLX1(HOX11) is more common (Karrman et al. 2009; Marks 
et al. 2009), causing over-expression of the affected genes. Over-expression of TLX1 is 
associated with good prognosis in T-ALL (Baak et al. 2008). 
In addition to chromosomal translocations, other genetic lesions essential to 
induce overt leukemia include deletion or epigenetic silencing of CDKN2A at 9p21.3 and 
intra-chromosomal amplification of chromosome 21 (iAMP21) (Knudson 1971; Harewood et 
al. 2003). CDKN2A encodes p16INK4A and p14ARF, which are tumor suppressors, and 
inactivation of CDKN2A deactivates TP53 and retinoblastoma pathways. Deletions of 
CDKN2A occur in approximately 70% of T-ALL and 30% of B-cell precursor ALL (Bertin et 
al. 2003). iAMP21 is associated with poor prognosis. RUNX1 is located in this amplified area 
at chromosome 21, and multiple copies of this gene are identified as a recurrent change in 
ALL (Robinson et al. 2003; Robinson et al. 2007).  
MiRNAs harbor prognostic implications in ALL. The association between 
miRNA expression and prognostic parameters such CNS relapse, specific risk group, and 
disease recurrence is evident (Zhang et al. 2009). Pediatric ALL patients who develop CNS 
relapse compared to patients with non-CNS relapse show over-expression of miR-7, miR-
198, and miR-633 and under-expression of miR-126, miR-345, miR-222, and miR-551a 
(Zhang et al. 2009). Eighteen deregulated miRNAs are related to specific risk groups: 
standard risk, intermediate risk, and high risk (Zhang et al. 2009). In those patients with 
WBC<50 000 mm3 at diagnosis, over-expression of miR-100 is detectable (de Oliveira et al. 
2012).  
Hyper-leukocytosis and cytogenetic groups with unfavorable markers associate 
with an increased level of miR-16 (Kaddar et al. 2009). Higher level of miR-16 expression 
correlates with shorter disease-free survival in both B- and T-ALL and with shorter overall 
survival in T-ALL (Kaddar et al. 2009). Another study found expression of 31 miRNAs to be 
relative to the likelihood of disease-free survival. Of these, 14 miRNAs are considered 
independent prognostic markers (Schotte et al. 2011) and can discriminate between two 
groups of patients, one with a favorable expression profile and a 5-year disease-free survival 
of 89.4±7% and one with a less favorable profile and a 5-year disease-free survival of 
60.8±12% (Schotte et al. 2011). The other miRNAs associated with shorter overall survival 
are miR-146a, miR-181a/c, and miR-92a; an miRNA associated with longer overall survival 
is miR-221 in ALL patients (Ohyashiki et al. 2010; Wang et al. 2010). 
Several studies show an association between miRNAs and response to treatment 
in ALL cases. MiRNAs identified in predicting prednisone response and also early 
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prednisone responses are miR-18a, miR-193a, miR-218, miR-532, miR-550, miR-625, miR-
633, and miR-638 (Zhang et al. 2009; Xu et al. 2011). In addition, a low level of miR-454 
expression is associated with L-asparaginase resistance, and expression of 20 miRNAs with 
vincristine and/or daunorubicin resistance (Schotte et al. 2011). Combination of the drugs 
allows rapidly eradication of most tumor cells and induce remission, which means presence 
of leukemic blasts <5% in the bone marrow, normal blood cells, and no tumor cells in blood, 
and absence of other signs and symptoms of the disease. 
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5.3.2. Acute myeloid leukemia (AML) 
 
5.3.2.1. Clinical characteristics and treatment of acute myeloid leukemia 
 
In AML, immature leukemic blasts accumulate in the bone marrow, peripheral blood, and 
sometimes in soft tissue. The most common acute leukemia in adults is AML, which accounts 
for about 80% of acute adult leukemias. Its annual incidence is 2.7/100 000, and it is slightly 
male predominant (Cornell and Palmer 2012). Median age at diagnosis is about age 72. 
Approximately 120 cases are diagnosed each year in Finland (Elonen 2007). Although the 
etiology of AML is mainly unknown, some associated risk factors are exposure to ionizing 
radiation, petroleum, benzene, and benzene-containing compounds, and smoking (Estey and 
Dohner 2006; Cornell and Palmer 2012). Germline Runx-1 mutations and some autosomal–
recessive disorders such as Bloom syndrome, fanconi anemia, and ataxia telangiectasia 
elevate AML risk (Cornell and Palmer 2012).  
Definitions of subtypes of AML were updated by the World Health 
Organization (WHO) based on genetic and clinical factors in 2008 (Table 5) (Cornell and 
Palmer 2012). This system has mainly replaced the French-American-British (FAB) 
classification which is based on cell morphology and maturity and defines AML as subtypes 
M0 through M7.  
WBC counts in AML patients may be high, normal, or low. The risk for 
infection is high, because of lack of WBCs or poorly functioning WBCs, or both (Cornell and 
Palmer 2012). When the blast count is more than 50, 000, leukostasis that is due to leukemic 
blasts’ blocking of capillary blood flow is more common. This phenomenon is an ontological 
emergency and needs to be treated quickly with leukopheresis. The symptoms are shortness 
of breath, cardiac dysfunction, severe muscle aches or cramping, and ocular, neurological, or 
cognitive dysfunction. 
Diagnosis is based on findings with flow cytometry, and with cytogenetic and 
molecular genetics by use of bone marrow biopsy and aspirate. To diagnose AML, detection 
of a 20% blast count in bone marrow aspirate or peripheral blood is necessary (Vardiman et 
al. 2002). AML risk groups are favorable, with a 5-year survival rate of 55 to 65%, 
intermediate at 38 to 40%, and unfavorable at 11 to 15% (Slovak et al. 2000; Grimwade et al. 
2004). Risk-group classifications aid in anticipating chemotheraphy response, relapse risk, 
and overall survival. Features related to poor prognosis in AML include advanced age, 
WBC>30 000, antecedent hematological disorders such as MDS (myelodysplasia), 
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myeloproliferative neoplasms (MPN), and therapy–related myeloid neoplasms (Estey 2001; 
Bello et al. 2011). In patients over age 60, occurrence of unfavorable cytogenetics is 23% 
compared to 15% in those less than 60 (Grimwade et al. 2010).  
Treatments used in AML are induction and post-remission therapy by use of 
chemotherapy and allogeneic bone marrow stem cell transplantation (Estey and Dohner 2006; 
Cornell and Palmer 2012). After achievement of an undetectable level of leukemic cells by 
induction chemotherapy, consolidation is given to maintain remission (Cornell and Palmer 
2012). The great number of cases who receive no consolidation therapy will experience 
relapse within 4 to 6 months of initial treatment (Cassileth et al. 1988). Despite initial 
remission, relapse is common (Derolf et al. 2009). Although AML treatment has improved, 
5-year survival for patients diagnosed in 2006-2010 was 21.4% (Pulte et al. 2010). Higher 
mortality has been seen in elderly patients and in those with poor performance status with 
intensive induction chemotherapy (Appelbaum et al. 2006a; Koreth et al. 2009). Finding 
novel therapeutic approaches is therefore necessary, particularly in this group of patients. 
 
 
Table 5. 2008 WHO classification of AML 
 
AML with recurrent genetic abnormalities 
 
a. AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
b. AML with inv(16)(p13;1q22) or t(16;16) (p13.1;q22) 
c. APL with t(15;17)(q22;q12); PML-RARA 
d. AML with t(9;11) (p22;q23); MLLT3-MLL 
e. AML with t(6;9)(p23;q34); DEK-NUP214 
f. AML with inv3(q21q26.2) or t(3;3) (q21;q26.2); RPN1-EVI1 
g. AML (megakaryoblastic) with t(1;22) (p12;q13); RBM15-MKL1  
h. Provisional entity:AML with muated NPM1 
j. Provisional entity: AML with mutaed CEBPA 
 
AML with MDS (myelodysplasia)-related changes   
Therapy-related myeloid neoplasms 
AML, not otherwise specified 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
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5.3.2.2. Genetic alteration in acute myeloid leukemia  
 
Cytogenetic and genetic alterations are regarded as important prognostic factors in AML. By 
the WHO system, AML patients are classified into three risk groups (poor, intermediate, and 
favorable) based on cytogenetic changes (Grimwade et al. 1998; Byrd et al. 2002). Balanced 
translocations, t(15;17), t(8;21), t(16;16), and inv(16), are associated with favorable 
prognosis (Appelbaum et al. 2006b). Those patients with a normal karyotype are classified in 
an intermediate group risk and comprise 40% of all patients (Grimwade et al. 2004). NPM1 
and CEBPA mutations are associated with favorable outcome, and likelihood of achieving 
complete remission is higher in those patients with mutated NPM1 or CEBPA in the absence 
of the FLT3 receptor; overall survival has also improved in this group (Schlenk et al. 2008). 
FLT3 mutations are associated with poor prognosis and lead to internal transmembrane 
mutation duplications (FLT3/ITD) with activation of the FLT3 receptor tyrosine kinase. 
NPM1 mutations occur in 50 to 60% and FLT3 mutations in 30% of cases (Falini et al. 2007; 
Kottaridis et al. 2001). Study of the effect of DNMT3A mutation status on prognosis of AML 
patients indicates that overall survival and relapse-free survival is worse in patients with 
mutation than in those with the wild type (Ribeiro et al. 2012).  
Comparing miRNA profiling of AMLs carrying FLT3-ITD with FLT3 wild-
type patients reveals three up-regulated miRNAs (miR-10a, miR-10b, and miR-155) in FLT3-
ITD. Over-expressed miR-124, miR-128-1, miR-194, miR-219-5p, miR-220a, and miR-320 
positively correlate with the risk for an event such as failed remission, relapse, or death (Seca 
et al. 2010). However, a correlation exists between higher miR-181a expression and higher 
complete remission rate, longer overall survival, and a trend toward longer disease-free 
survival. Elevated level of this miRNA also is associated with higher complete remission rate 
and longer disease-free survival in patients with poor molecular risk such as those of the 
FLT3-ITD and NPM1 wild type (Schwind et al. 2010). Up-regulation of miR-181a and miR-
335 and down-regulation of miR-194 and miR-34a are associated with the GEBPA mutation 
(Marcucci et al. 2008). Some of the miR-181 family target genes (TLR4, CARD8, CASP1, 
and IL1B) show an inverse correlation with expression of members of this family that 
suggests a link between down-regulation of the miR-181 family and AML aggressiveness 
(Seca et al. 2010).  
In patients with poor- and intermediate-prognosis karyotypes, the over-
expressed miR-191 and miR-199 are associated with shorter overall survival and event-free 
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survival (Garzon et al. 2008). Level of miR-9 and let-7d is low in good-prognosis patients, 
while being high in intermediate and adverse AML (Dixon-McIver et al. 2008). 
Evidence shows the role of miRNAs in the mechanism of resistance to anti-
leukemia chemotherapies, and drug-resistant subtypes present specific miRNA signatures 
(Zhao et al. 2010; Zimmerman et al. 2010; Schotte et al. 2011). MiR-136 is found at a lower 
level in an AML HL-60-resistant cell line than in parental cells and indicates a link between 
this miRNA and multidrug resistance of leukemic cells (Zhao et al. 2010). Cytarabine is the 
backbone of chemotherapy used mainly in treatment of AML. It kills cancer cells by 
interfering with DNA synthesis. When the cell line is pretreated with an anti-miR-21, the 
potency of cytarabine increase in an AML-derived cell line (Li et al. 2010). Thus, 
identification and targeting of miRNAs involved in drug resistance may aid us in developing 
anti-cancer drugs with lower side effects and mortality rates. 
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AIMS OF THE STUDY 
 
The general aim of the study was to identify miRNAs related to prognosis and drug response 
by means of the latest versions of miRNA microarrays. 
 
The specific aims of this thesis were to identify  
 MiRNA signatures associated with colorectal cancer and with KRAS status 
 MiRNA signatures associated with resistance to anti-EGFR monoclonal antibody 
treatment in chemorefractory metastatic colorectal cancer patients with wild-type 
KRAS/BRAF and with third- to sixth-line anti-EGFR monoclonal antibody treatment.  
 MiRNAs associated with metastasis and progression in primary tumors of giant cell 
tumor of bone. 
 Any significant association between expression of miRNAs and overall survival, and 
differences in miRNA expression in matched diagnosis-relapse samples in acute 
lymphoblastic leukemia. 
 Any miRNA signature associated with drug response in acute myeloid leukemia. 
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MATERIALS AND METHODS 
 
1. Patient specimens (I-V) 
 
Table 6 is a summary of the patients included in the studies. 
 
1.1. Study I: FFPE tissue sections were collected from the primary tumors of 60 metastatic 
CRC (mCRC) patients at Helsinki and Turku University Central Hospital before any 
treatment was initiated. Of these 60, 30 were female and 30 male, mean age 61 years. In 44 
patients, the site of the primary tumor was the colon and in 16 patients was the rectum. The 
percentage of tumor cells was provided by pathologists at the Helsinki and Turku University 
Central Hospitals. Tumor content ranged from 30 to 90% in both mutated and non-mutated 
KRAS sample groups.   
 
1.2. Study II: Included were 33 FFPE sections from primary tumors of 33 patients with 
mCRC treated at Helsinki University Central Hospital and at Turku University Central 
Hospital. All the primary tumors were from the diagnosis period, prior to the start of any 
treatment with wild-type KRAS and BRAF status. The patients experienced no other 
malignancy and had third- to sixth-line treatment with cetuximab or panitumab and with or 
without irinotecan, and were chemorefractory or intolerant to irinotecan, oxaliplatin, and 5-
fluorouracil. Based on their responses to anti-EGFR monoclonal antibody treatment, the 
patients were divided into two groups; a disease control and a progressive disease group. 
 
1.3. Study III: The primary tumors from 10 GCTB patients were collected at the Rizzoli 
Orthopaedic Institute, Bologna, Italy. No primary tumor had been subjected to treatment. 
Both fresh frozen sections and FFPE sections obtained from each patient were used in our 
study. Of ten patients, two were at stage I, two at stage II, and the remaining six patients at 
stage III. Five patients developed lung metastases, but the other five developed none. The 
percentage of tumor cells equal to or more than 90% was estimated for each sample. In 
addition, NFIB protein expression was evaluated in 74 FFPE samples of primary GCTB 
including 45 disease-free and 29 metastatic.  
 
1.4. Study IV: A total of 90 archived bone marrow core biopsy samples came from 79 
pediatric patients diagnosed at Helsinki University Hospital, Finland, during 2000-2006. The 
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clinical data of these patients were extracted from the Nordic Society of Paediatric 
Haematology and Oncology (NOPHO) ALL database. The patients were treated according to 
the NOPHO-2000 and Interfant treatment protocols for ALL, with 11 pairs being available 
from the same patients, one sample at diagnosis and one at relapse. We categorized the ALL 
patients into 10 groups based on their cytogenetic features. Screening of the genomic 
aberrations was done by either one or more of these methods: interphase fluorescence in situ 
hybridization (FISH), array CGH, and PCR. Key characteristics of the ALL patients are in 
Table 1 in Study II. Eight bone marrow samples from healthy donors, obtained from an 
archived May–Grünwald–Geimsa-stained bone marrow aspirate smear, served as controls. 
 
1.5. Study V: From 33 AML patients, 33 bone marrow core biopsy specimens at the time of 
diagnosis (before initiation of any treatment) were included in our study. Of these patients, 15 
were chemorefractory and 18 chemosensitive (Table 1 in V). All patients were diagnosed and 
treated at Helsinki University Central Hospital, Finland, during 1993-2009, with treatment 
according to national AML protocols (AML-92 or AML-04). Patients without complete 
remission or with early relapse were defined as chemorefractory, and those patients with 
complete remission by the end of their first induction with following consolidation were 
defined as chemosensitive. None of the chemosensitive patients received allogeneic stem-cell 
transplantation.  
 
Table 6. Specimens and studies 
Study Type of cancer 
Total 
no.sample 
Method used in study 
miRNA microarray qRT-PCR IHC Affymetrix array 
Study I CRC 60     
Study II CRC 33     
Study III GCTB 84    
Study IV ALL 90     
Study V AML 33     
IHC, immunohistochemistry 
 
2. Ethical permission 
 
Studies I and II were approved by the HUS ethics committee as no.  173/13/03/02/09. The 
research protocol was approved for Study III by the ethics committee of the Rizzoli Institute, 
Bologna, Italy. The appropriate Institutional Review Boards and the National Authority for 
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Medico-legal Affairs approved Study IV. The samples for Study V were collected with 
approval from the HUS Ethics committee, Department of Medicine, Helsinki, Finland, and 
Valvira in Finland. 
 
3. Nucleic acid extraction (I-V) 
 
To extract DNA from tumor tissue samples, the QIAamp DNA FFPE Mini Kit (Qiagen, 
Valencia, CA) was used for Studies I and II. Total RNA was extracted in Study III with 
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and in Studies I, II, IV, and V with the 
miRNeasy FFPE Mini Kit (Qiagen) according to the manufacturer’s protocols. The quality of   
RNA was assessed with the RNA 6000 chip, and miRNA with the small RNA chip (Agilent 
Technologies, Santa Clara, CA, USA). The control RNA sample from colon tissue used in 
Studies I and II was commercially available (FirstChoice® Human total RNA, Applied 
Biosystems/Ambion, Austin, TX, USA). 
 
4. Mutation analysis (I & II) 
 
To screen KRAS and BRAF mutations in CRC patients (Studies I and IV), we used the 
TheraScreen KRAS mutation kit (Qiagen, DxS Ltd, Manchester, UK) and the BRAF Mutation 
Test Kit (Qiagen, DxS Ltd), using a real-time PCR assay. The patients with wild-type KRAS 
were included in the BRAF mutation test, because KRAS and BRAF mutations are nearly 
mutually exclusive in CRC (Frattini et al., 2004).  
 
5. MiRNA microarray (I-V) 
 
We performed an miRNA expression profile with Agilent’s miRNA Microarray system V2 
(comprising 723 human and 76 human viral miRNAs, Sanger database v.10.1) for Studies I 
and II and Agilent’s miRNA Microarray system V3 (comprising 866 human and 89 human 
viral miRNAs catalogued in the Sanger miRNA database v12) for Studies III, IV, and V. The 
RNA was labeled and hybridized for 20 hr according to the miRNA complete labeling and 
hybridization kit protocol version 2.0. The microarrays were then washed with prepared 
washing buffers and scanned with Agilent's scanner (G2505B, Agilent Technologies). 
Preprocessing of Agilent's scanner images was performed with Agilent's feature extraction 
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software with default parameters. Data were analyzed with GeneSpring Software Version 
11.0.2. 
 
6. Quantitative real time RT- PCR (qRT-PCR) (I-V) 
 
In order to confirm the microarray results, we performed qRT-PCR for selected miRNAs in 
Studies I to V. In brief, cDNA was generated from total RNA with the miScript Reverse 
Transcription Kit (Qiagen, Valencia, CA) according to manufacturer’s instructions. Then 
qRT-PCR was done by use of the SYBR Green miScript PCR system (Qiagen) on a Light-
cycler, software v.3.5 (Roche Applied Science, Mannheim, Germany). The primer of selected 
miRNAs and endogenous control U6 came from Qiagen.  
In Study II, we measured the level of two predicted target genes of differentially 
expressed miRNA by use of the RT² SYBR Green PCR Master Mix (Qiagen) with a Light-
cycler, software v.3.5 (Roche Applied Science), following the manufacturer’s guidelines. 
cDNA was synthesized from total RNA by use of the RT2 First Strand kit (Qiagen). 
Housekeeping gene human 18SrRNA, SLC26A3, and ATN1 primers came from Qiagen.  
In Study III, to verify identified differentially expressed genes by array 
affymetrix, the High Capacity cDNA Archive kit (Applied Biosystems) and TaqMan 
Expression Assays (Applied Biosystems) were our choice, used according to manufacturer’s 
instructions. The ACTB gene as a housekeeping gene was commercially available (Applied 
Biosystems). The relative quantification (RQ) of both miRNA expression and gene 
expression were calculated with formula 2-∆∆CT. 
 
7. Immunohistochemistry (III) 
 
In Study III, the expression level of NFIB protein was evaluated by immunohistochemistry 
(IHC) with Streptavidin-biotin peroxidase DAB rabbit/mouse (Dako, Glostrup, Denmark) 
detection systems utilizing  mouse monoclonal anti-NFIB antibody (1:1000, Abnova). Those 
samples with  less than 10% NFIB-positive cells were considered negative, those with  25% 
positive cells considered weakly positive, with 25 to 49% moderately positive, and with more 
than 50% positive cells strongly positive. When the NFIB immune reactivity was moderate to 
strong, NFIB was over-expressed, but in those negative to weakly immune, reactivity was 
under-expressed.  
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8. Gene expression analysis with Affymetrix microarrays (III) 
 
The mRNA data used in Study III were previously obtained by use of Affymetrix Human 
Genome U133 Plus 2.0 (Affymetrix, Santa Clara, CA, USA) for the same samples in study 
by Pazzaglia et al. (2010). In brief, the cDNA is converted into a double-stranded state and 
then transcribed into cRNA labeled with biotin in an in vitro trascription reaction (IVT). The 
IVT reaction is a linear amplification (usually 20-100 fold) of the original mRNA. The 
biotinylated cRNA is then hybridized on array and afterwards a streptavidin-phycoeytrin 
conjugate is added that binds biotin and emits fluorescent light after laser excitation. After 
appropriate washings, the chips were analyzed with Affymetrix® GeneChip® Command 
Console® Software (AGCC). 
 
 
 
 
 
 
 
 
 
 
  
48 
 
RESULTS AND DISCUSSION 
1. MiRNA expression profiling in colorectal cancer and association of miRNA 
expression with KRAS status (I) 
In Study I, we compared miRNA profiling of all primary tumors of mCRC (55 samples with 
and without KRAS mutation) with normal colon tissue. We removed five samples from our 
further analysis, because they carried the BRAF mutation. The analysis revealed 46 altered 
miRNAs (q<0.05), in which 39 were significantly under-expressed and 7 significantly over-
expressed (Table 1 in Study I). Our finding is accordance with Lu et al. (2005) that 
expression level of miRNA is lower in cancer than in normal tissue. Our study revealed 19 
identified miRNAs as novel. The miRNAs with the highest fold changes were under-
expressed miR-1 (FC=60.2), miR-195 (FC=35.7), and miR-143 (FC=26.7), and over-
expressed miR-494 (FC=25.2). High-throughput sequencing also found a lower expression 
level of miR-1 and miR-195 in CRC than in paired normal mucosa (Hamfjord et al. 2012). 
MiR-1 functions as a tumor suppressor by down-regulating the MET oncogene, and its down-
regulation may enhance CRC progression (Reid et al. 2012).  
Next we investigated the impact of KRAS status on miRNA expression. KRAS is 
an important gene in the EGFR signaling pathway which can predict resistance to anti-EFGR 
treatment; treatment success depends on the presence of the KRAS wild type. On the other 
hand, 35 to 40% of CRC patients carry the KRAS mutation. Thus, identification of novel 
markers which can improve the strategy of treatment in this group of patents is essential. 
The expression level of four miRNAs significantly discriminated between 15 
CRC patients with and 40 without the KRAS mutation (q<0.05). MiR-92a, miR-127-3p, and 
miR-486-5p were over-expressed, and miR-378 was under-expressed in the mutated KRAS 
group. Higher expression of miR-127-3p and miR-92a were significantly confirmed with 
qRT-PCR. In accordance with our finding, up-regulation of miR-92 is detected in several 
cancers such as CRC (Ng et al. 2009). This miRNA, along with other miRNAs in the miR-
17-92 cluster, is involved in promoting cell proliferation and anti-apoptotic processes of 
cancer cells, and in sustaining angiogenesis (Mendell 2008). Thus, the role of elevated miR-
92 in mutated KRAS patients may in part clarify this group’s inferior outcome (Andreyev et 
al. 1998).  
An elevated level of miR-486-5p in mutated KRAS samples was also detected 
by Ragusa et al. (2010), a level which may be due to activation of KRAS signaling. MiR-486-
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5p is one of the miRNA discriminators between squamous cell carcinoma and normal lung 
tissue (Tan et al. 2011). 
MiR-127-3p is up-regulated in enriched lung adenocarcinoma tumor-initiating 
cells from the A549 cells, and its expression trend is validated in A549 cell line- and primary 
lung- adenocarcinoma samples, with suggestions that miR-127-3p may play an important role 
in regulating the bio-behavior of tumor-initiating cells (Lin et al. 2012).The level of miR-
127-3p as a potential serum biomarker in esophageal squamous cell carcinoma is also higher 
in patients’ serum than in control individuals’ serum (Zhang et al. 2010). 
Target genes predicted by at least four of six databases—to minimize the false 
positivity—for differentially expressed miRNAs in CRC vs. normal were 828, and in mutated 
vs. wild-type KRAS were 65 common genes.  Then, predicted target genes were screened to 
seek their significant involvement in biological networks. Among the pathways, the G 
protein-coupled receptor (GPCR) -signaling pathway was one of the most significant. GPCRs 
regulate cells (Fichter et al. 2010), and effects of activated GPCR on growth-promoting are 
mediated via activation of receptor tyrosine kinases such as EGFR (Shah and Catt 2004; 
Wetzker and Bohmer 2003). Some target genes of discriminator miRNAs between CRC, with 
and without KRAS mutation, were RGS3, TOB1, and HNF1B. These target genes are involved 
in apoptosis, dedifferentiation, and anti-proliferative processes (Nishiura et al. 2009; Buchner 
et al. 2010). Thus, our observations suggest that miRNAs and their target genes may play an 
important role in mechanisms of resistance to anti-EGFR monoclonal antibody treatment in 
mutated KRAS tumors and may prove useful for developing treatment strategies in this group 
of patients. 
 
2. MiRNA expression in anti-EGFR monoclonal antibody-treated metastatic colorectal 
cancer (II) 
 
Half the mCRC patients with no mutation in KRAS and BRAF fail to respond to anti-EGFR 
monoclonal antibody treatment. To see whether any association exists between miRNA 
profile and treatment response in this group of patients, first the cases were screened for 
KRAS and BRAF mutations, and those with either KRAS or BRAF mutations we removed 
from analysis. We examined only the primary untreated tumors of mCRC that had undergone 
third-to sixth-line treatment with cetuximab or panitumab. The patients’ division into two 
groups: DC (including responders and stable disease) and PD—evaluation of response to 
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anti-EGFR monoclonal antibody treatment—was based on the Response Evaluation Criteria 
for solid tumors 1.0 (Therasse et al. 2000).  
We found two differentially expressed miRNAs: up-regulated miR-31* and 
down-regulated miR-592, between PD and DC. Their expression trend was verified by qRT-
PCR. The function of miR-31* is not well known in CRC, but its higher expression is 
detectable  in malignantly transformed oral leukoplakia when compared to oral leukoplakia 
and oral squamous cell carcinoma tissues (Chang et al. 2012; Xiao et al. 2012). Evidence 
shows that miR-31* also plays a biological function in cancer development (Xiao et al. 
2012). 
MiR-592 is associated with the transition of normal colon to carcinoma (Oberg 
et al. 2011), being down-regulated in hepatocellular carcinoma (Wang et al. 2012). The level 
of miR-592 is also lower in deficient mismatch repair (dMMR) than in proficient mismatch 
repair (pMMR) CRC (Sarver et al. 2009). dMMR cells show resistance to anti-metabolites 
and to platinum drugs such as 5-fluorouracil and cisplatin (Aebi et al. 1996; Drummond et al. 
1996). 
By applying strict criteria to screen potential target genes of miR-31* and miR-
592, we found 592 common genes in four databases. SLC26A3 and ATN1, miR-31* target 
genes that are drug-related genes in CRC, were verified by qRT-PCR to assess their 
expression level in DC and PD groups. In the PD group, expression levels of SLC26A3 and 
ATN1 detected were lower than for the DC group. A lower expression level of ATN1 occurs 
in chemoradiation-resistant colorectal cell lines (Spitzner et al. 2010). SLC26A3 is under-
expressed in the early neoplastic process and in CRC compared to normal samples 
(Schweinfest et al. 1993; Byeon et al. 1996; Antalis et al. 1998). SLC26A3 inhibits cell 
growth and colony formation in numerous cancers such as CRC (Chapman et al. 2002). In 
mucinous CRC, a subtype of CRC, the level of SLC26A3 is lower than for the non-mucinous 
form, clinically; 5-year overall survival is worse in mucinous CRC, and lymph nodes are 
involved more extensively (Kim et al. 2011). The function of this gene is related to 
tumorigenesis (Kim et al. 2011). Its expression level is associated with disease control and 
progression-free survival in KRAS wild-type CRCs, and it is one of the four genes involved in 
the prediction classification model of cetuximab efficacy (Baker et al. 2011). 
When we divided the patients into two groups based on their overall miRNA 
expression by unsupervised clustering and then by applying Kaplan-Meier survival analysis, 
the overall survival with mCRC between these groups significantly differed (p=0.03). 
Seventy-five miRNAs were differentially expressed between the two groups (Table 1 in 
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Study II). Among miRNAs, up-regulated members of the let-7 family (let-7f, let-7g, let-7d, 
let-7i, let-7a, let-7e, and let-7b) appeared in the group of patients with poorer prognosis. Let-
7f was verified by qRT-PCR (p<0.005). Pearson correlation analysis was unable to establish 
any significant negative correlation between PCR data as to let-7f and overall survival, but it 
showed a trend toward poorer survival for CRC patients who showed higher expression of 
let-7f (R=-0.3, P=0.08). Members of the let-7 family act as potential tumor suppressors, and 
they are down-regulated in various types of cancers compared to normal tissue. Their higher 
levels are, however, associated with poorer survival, which is in accordance with our results 
(Ali et al. 2010; Silva et al. 2011; Zuo et al. 2011). Higher expression of let-7 in lung cancer 
and in myelodysplastic and pancreatic cancers correlates with poor overall survival (Ali et al. 
2010; Silva et al. 2011; Zuo et al. 2011). We studied also the correlation between each 
miRNA and overall survival with the Cox proportional hazards regression model, and 11 
miRNAs were significantly correlated with overall survival (Table 2 in Study II). This 
analysis showed two miRNAs to be associated with poor overall survival (up-regulated miR-
140-3p and down-regulated miR-1224-5p), as did cluster analysis. 
An association exists between epigenetic silencing of miR-1224 and 
progression of bladder cancer. Moreover, up-regulated miR-1224-5p correlates with complete 
pathological response to neo-adjuvant chemo-radiotherapy in locally advanced rectal cancer 
(Della Vittoria Scarpati et al. 2012). The level of miR-140 is high in colon cancer stem-like 
and its blocking in resistant cells sensitizes them to 5-fluorouracil treatment (Song et al. 
2009). The miRNAs identified in our study may play an important role in CRC biology and 
may serve as prognostic predictors. 
 
3. Prognostic value of miRNA in giant cell tumor of bone (III) 
 
Despite numerous studies on GCTB, information and knowledge are lacking regarding the 
role of miRNA in pathogenesis of GCTB and also in tumor progression. To evaluate whether 
any miRNA is involved in GCTB progression and metastasis, first we compared the miRNA 
profiling, and then we integrated mRNA and miRNA expression data.  
Regarding 12 differentially expressed miRNAs identified between metastatic 
and non-metastatic tumors: 6 miRNAs were absent from all non-metastatic but detectable in 
metastatic tumors (miR-513a-5p and miR-let-7a* in 60%, and miR-224, miR-10b*, miR-934, 
and miR-876-5p in 40%), and 5 miRNAs were absent from all metastatic but expressed in 
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non-metastatic tumors (miR-136 in 60%, and miR-542-5p, miR-505*, miR-542-3p, and miR-
1 in 40%); expression level of miR-494 was higher in metastatic tumors.  
Verification of miR-1, miR-494, miR-136, and miR-513a-5p by qRT-PCR 
showed an expression trend similar to that shown by microarray analysis. However, only 
miR-136 was significantly differentially expressed between metastatic and non-metastatic 
tumors, but its function related to cancer is still unknown. MiR-1, miR-542-5p, and miR-542-
3p as tumor suppressors have been identified in numerous cancers such as thyroid 
carcinogenesis, head and neck squamous cell carcinoma, and neuroblastoma (Bray et al. 
2011; Leone et al. 2011; Nohata et al. 2011; Zhao et al. 2011). MiR-542-3p regulates the cell 
cycle and is a cell-proliferation inhibitor. A higher level of miR-224 occurs in various human 
tumor types including colorectal, hepatocellular, and renal cancers (Kang et al. 2003; Mees et 
al. 2009; Mencia et al. 2011). Similarly, over-expression of miR-224 is associated with breast 
cancer invasion and CRC progression, as well as with invasion and metastasis in pancreatic 
ductal adenocarcinoma; this suggests that miR-224 is an onco-miR (Nguyen and Massague 
2007; Arndt et al. 2009; Huang et al. 2012). 
When mRNA and miRNA array data were combined, eight target genes 
(PDPN, BAALC, NR2F1, TNC, NET1, SETBP1, NFIB, and FLRT2) showed an inverse 
correlation with miRNA identified in GCTB, and these eight were concordant with the list of 
miRNA-predicted targets genes in databases (Figure 9 and Table 3 in Study III). Further, the 
higher expression level of NFIB, the miR-136 target gene, in metastatic GCTB, was verified 
by use of qRT-PCR, which we found by analysis of array data. A similar pattern of NFIB 
expression at protein level by IHC was confirmed not only in the same samples but also in a 
larger series of GCTB (Figure 10). The primary tumor of metastatic GCTB produced 
moderate to strong immunostaining (>25% positive cells), but non-metastatic tumors 
produced weak immunostaining. The expression level of NIFB significantly correlated with 
rate of metastasis but not with confounding factors such age, sex, size of tumor, or outcome. 
The role of over-expressed NFIB has been evident in tumor progression. Moreover, NFIB 
leads to increased cell growth and reduces apoptosis in a murine hematopoietic cell line and 
in triple-negative breast cancer, and it acts as an oncogene in small-cell lung cancer (Dooley 
et al. 2011; Moon et al. 2011; Rice et al. 2011).  
TNC over-expression inversely correlated with undetectable miR-1 and miR-
542-5p in metastatic GCTB. A high level of TNC is a metastasis risk factor and associates 
with poor prognosis in GCTB (Pazzaglia et al. 2010).  
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To examine the biological and functional networks, we performed pathway 
analysis only with the differentially expressed mRNAs, the target genes of differentially 
expressed miRNAs that also inversely correlated with miRNA expression. As a result, we 
identified the FOXA1 pathway as related to miRNAs’ target genes. FOXA1 as a central 
component of this pathway is the first class of forkhead-type proteins identified in mammals. 
NFIB, the miR-136 target gene, and NR2F2, the miR-513a-5p target gene, belong to FOXA1. 
Because FOX proteins are important in many biological processes such as proliferation, 
migration, and invasion (Myatt and Lam 2007), the induction or repression of their function 
can result in tumorigenesis and cancer progression (Myatt and Lam 2007); this may, in part, 
explain the trend of some primary GCTB cases toward development of metastases. 
 
Figure 9. Over-expressed and under-expressed miRNA target genes in metastatic vs. non-metastatic GCTB. 
 
 
Figure 10. NFIB immunostaining and mRNA level in GCTBs, NM=non-metastatic; M=metastatic 
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4. Detection of novel prognostic markers in acute lymphoblastic leukemia by miRNA 
profiling (IV) 
 
Our analysis showed 93 differentially expressed miRNAs in pediatric ALL vs. normal bone 
marrow samples, including 37 up-regulated and 56 down-regulated miRNAs (Tables 7 & 8). 
The differences in miRNA expression between ALL and normal samples were 
distinguishable by hierarchical clustering as well (Figure 11). Although some earlier studies 
demonstrate miRNA profiling in ALL (Mi et al. 2007; Zanette et al. 2007; Schotte et al. 
2009; Zhang et al. 2009), only two studies evaluate miRNA profiling in pediatric ALL, and 
the up-regulation of miR-181a/b, miR-146a, miR-155, miR-34a, and miR-130b seen in our 
ALL patients is similar to that reported in those two pediatric ALL studies: Schotte et al. 
2009 and Zhang et al. 2009. A high level of miR-130b and low levels of miR-223, miR-451, 
and miR-22 appeared in our study, as they did during comparison of ALL and AML in 
another study (Mi et al. 2007). However, let-7e and miR-19a have shown expression patterns 
in other ALL studies that differ from the pattern in ours (Zanette et al. 2007; Schotte et al. 
2009) (unpublished data). 
 
Table 7. Up-regulated miRNAs in pediatric ALL as compared to normal bone marrow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MiRNA q-value FC miRNA q-value FC  
hsa-miR-181b <0.0001 12.19 hsa-miR-125b 0.002 3.03 
hsa-miR-128 <0.0001 9.91 hsa-miR-574-3p <0.0001 3.03 
hsa-miR-181a <0.0001 7.53 hsa-let-7e <0.001 3.02 
hsa-miR-892b <0.0001 6.15 hsa-miR-625 0.001 2.99 
hsa-miR-1290 <0.0001 5.21 hsa-miR-221 0.003 2.92 
hsa-miR-1288 <0.0001 5.13 hsa-miR-130b <0.001 2.72 
hsa-miR-1305 <0.0001 5.03 hsa-miR-198 <0.0001 2.54 
hsa-miR-146a 0.003 4.55 hsa-miR-320d <0.001 2.46 
hsa-miR-501-5p <0.0001 4.53 hsa-miR-877* 0.009 2.46 
hsa-miR-500 <0.0001 4.25 hsa-miR-1914* <0.0001 2.36 
hsa-miR-222 0.007 4.03 hsa-miR-34a 0.006 2.29 
hsa-miR-155 <0.0001 4.01 hsa-miR-766 0.001 2.21 
hsa-miR-513b <0.0001 3.96 hsa-let-7f-1* 0.033 2.21 
hsa-miR-1246 <0.0001 3.8 hsa-miR-720 0.001 2.09 
hsa-miR-513a-5p <0.0001 3.79 hsa-miR-760 0.001 2.07 
hsa-miR-513c <0.0001 3.78 hsa-miR-630 0.001 2.06 
hsa-miR-23b 0.001 3.29 hsa-miR-320b 0.002 2.03 
hsa-miR-199a-3p 0.003 3.17 hsa-miR-1268 0.003 2.01 
hsa-miR-331-3p <0.0001 3.09    
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Table 8. Down-regulated miRNAs in pediatric ALL as compared to normal bone marrow  
 
Figure 11. Hierarchical clustering of samples based on miRNA expression. The ALL patients have a distinct 
expression profile separating them from normal bone marrow control samples. 
miRNA q-value FC miRNA q-value FC  
hsa-miR-144 <0.0001 95.95 hsa-miR-1306 <0.0001 3.27  
hsa-miR-144* <0.0001 62.16 hsa-miR-106b <0.0001 3.18  
hsa-miR-451 <0.0001 50.76 hsa-miR-7 <0.001 3.09  
hsa-miR-96 <0.0001 24.54 hsa-miR-19a <0.0001 3.07  
hsa-miR-486-5p <0.0001 18.53 hsa-miR-29c <0.001 2.99  
hsa-miR-185 <0.0001 16.28 hsa-miR-18b 0.005 2.98  
hsa-miR-194 <0.0001 11.43 hsa-miR-424* <0.001 2.84  
hsa-miR-183 <0.0001 10.82 hsa-miR-19b <0.001 2.82  
hsa-miR-223 <0.0001 9.31 hsa-miR-374a 0.005 2.76  
hsa-miR-223* <0.0001 8.39 hsa-miR-15a <0.0001 2.74  
hsa-miR-101 <0.0001 8.38 hsa-miR-107 <0.0001 2.73  
hsa-miR-192 <0.0001 8.37 hsa-miR-29b 0.001 2.61  
hsa-miR-486-3p <0.0001 8.3 hsa-miR-1202 <0.0001 2.6  
hsa-miR-595 <0.0001 7.59 hsa-miR-29a 0.001 2.51  
hsa-miR-1228* <0.0001 6.04 hsa-miR-148b 0.006 2.5  
hsa-miR-148a <0.001 5.9 hsa-miR-30e <0.001 2.45  
hsa-miR-32* <0.0001 5.84 hsa-miR-25 <0.001 2.44  
hsa-miR-16 <0.0001 5.62 hsa-miR-16-2* 0.002 2.43  
hsa-miR-362-5p <0.0001 5.56 hsa-miR-652 0.024 2.36  
hsa-miR-215 <0.0001 5.49 hsa-miR-103 <0.0001 2.24  
hsa-miR-18a <0.0001 5.25 hsa-miR-1287 0.011 2.19  
hsa-miR-660 <0.0001 5.23 hsa-miR-26b 0.003 2.18  
hsa-miR-22 <0.0001 5.15 hsa-miR-212 <0.001 2.12  
hsa-miR-1180 <0.0001 4.85 hsa-miR-338-5p 0.005 2.1  
hsa-miR-532-5p <0.0001 4.75 hsa-let-7g 0.004 2.06  
hsa-miR-187* <0.0001 4.69 hsa-miR-590-5p 0.007 2.03  
hsa-miR-15b <0.0001 3.91 hsa-miR-1285 0.001 2.03  
hsa-miR-769-3p <0.0001 3.40   hsa-miR-27a 0.011 2.01  
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To see the correlation between miRNA expression and survival, we applied two 
approaches for data analysis. First we compared groups with and without events (relapse or 
death). In the first comparison, patients with an event showed down-regulation of miR-150 
versus that of patients without any event. MiR-150 is a lymphoid-specific and very important 
miRNA in hematopoiesis (Xiao et al. 2007; Vasilatou et al. 2010). Its deregulation occurs in 
several hematological malignancies including ALL (Zanette et al. 2007). MiR-150 functions 
as a tumor suppressor (Watanabe et al. 2011) and is reported to inhibit cell proliferation and 
to induce cell apoptosis in T-ALL (Ghisi et al. 2011). Moreover, our target analysis revealed 
ELK1 and PLP2 as being targets of miRNA-150, and of these, ELK1 is involved in the 
MAPK pathway and PLP2 in the metastatic process (Cohen-Armon 2007; Sonoda et al. 
2010). Duplication of the ELK1 oncogene at Xp11.23 occurs in ALL patients, and these 
patients show very poor prognosis (Yasar et al. 2010). Thus, down-regulated miR-150 in 
ALL cases with an event (relapse or death) may lead to over-expression of ELK1 and PLP2, 
and this may explain why these patients have an unfavorable prognosis. 
In our second approach, we performed unsupervised clustering of miRNA data 
from all patients and obtained two groups of patients who differed clearly in their miRNA 
expression pattern (Figure 1a in Study IV). Survival analysis and event-free survival by the 
Kaplan-Meier method showed that these two groups had significantly differing overall 
survival and event-free survival, independent of certain cytogenetic changes, of risk group, of 
immunophenotype, and of age (Figures 1b & 1c in Study IV). Among 28 significantly up-
regulated and 2 down-regulated miRNAs (q<0.05) in group 1 compared to group 2 (Table 1 
in Study IV), miR-423-5p (q=0.001), which was exclusively expressed in one group and 
totally absent from the other group, was selected, and we confirmed its expression pattern 
with qRT-PCR (p=0.005). Kaplan-Meier analysis of the qRT-PCR results from this miRNA 
revealed that higher expression of miR-423-5p was associated with better overall survival 
(p=0.04) but not with event-free survival. This association was independent of confounding 
factors: immunophenotype, age, risk group, cytogenetics. The expression of miR-423-5p was 
undetectable in the group of patients with poor prognosis.  
Although no correlation between miR-423-5p and progression exists thus far, 
two miR-423-5p target genes, SRA1/SCARF1 and FOXM1, showed an association with 
overall survival and prognosis in numerous cancers (Carter et al. 2006; Leoutsakou et al. 
2006; Ma et al. 2009). An inverse correlation appears between expression of SRA1 and 
prognosis and overall survival in ovarian cancer, and its higher expression is found in relation 
to aggressive ovarian cancer phenotypes (Scorilas et al. 2001; Leoutsakou et al. 2006). 
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FOXM1 is a survival-predictor gene in numerous cancers (Carter et al. 2006), and due to the 
inhibitory role of a reduced level of FOXM1 in leukemia-cell proliferation, this gene could 
prove useful in targeted therapy regimens for leukemia patients (Nakamura et al. 2010). 
Together, these findings may reveal the importance of the miR-423-5p role in survival by its 
negative regulation of these genes. 
Our analysis was unable to find any differences in miRNA expression between 
clinical risk groups (standard, intermediate, and high risk) which are clustered based on 
clinical and cytogenetic evaluation. 
Differentially expressed miRNAs, miR-654-5p and miR-431, were also 
identified in matched diagnosis-relapse samples. The role of the miR-431 target gene, PKD1, 
is known in endothelial cells for mediating signal transduction in association with 
angiogenesis by VEGF (Ha and Jin 2009). Angiogenesis is an essential factor for tumor 
growth (Ferrara and Davis-Smyth 1997), and on the other hand, based on the role of PKD1 in 
angiogenesis, it is a suitable target in order to develop targeted therapy in angiogenesis-
related diseases (Altschmied and Haendeler 2008). In considering this point, however, we 
must remember that changes in miRNA expression may be due more to treatment than to the 
original tumor cells. 
 
5. MiRNAs and the drug resistance of acute myeloid leukemia (V) 
 
The role of miRNAs in drug resistance of AML patients was not well known when we 
designed this study. We used core biopsy samples because their reliability has been 
investigated (Borze et al. 2011), and also because in all biopsies, tumor percentage was more 
than 80%. We compared the miRNA profile of core biopsy samples of AML, ones resistant 
to and sensitive to chemotherapy, to see whether any difference existed in their miRNA 
expression. MiRNA was considered as differentially expressed when the difference was more 
than a two-fold change, and the q-value was less than 0.05. After these filtrations, three 
miRNAs (miR-363, miR-532-5p, and miR-342-3p) remained. All were over-expressed in 
chemoresistant compared to chemosensitive patients. 
 The most significant miRNAs selected for verification by qRT-PCR showed an 
expression similar to that with microarray (Figure 12). Only the increased level of miR-363 
in chemoresistant versus chemosensitive patients was, however, significant (P=0.03).  
MiR-363 belongs to the oncogenic miR-17-92 cluster, leading to suggestions 
that members of this family may function similarly (Wald et al. 2011). Another miRNA, 
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miR-532-5p, is involved in tumor progression in melanoma, and its higher level is detectable 
in metastatic tumors but not in primary tumors (Kitago et al. 2009). The level of miR-532-5p 
is also high in ovarian carcinoma vs. borderline tissues (Lee et al. 2012). Involvement of 
miR-342-3p in different types of cancer has also revealed that while this miRNA is over-
expressed in primary multiple myeloma and acute promyelocytic leukemia, its expression is 
lower in polycythemia vera, or in essential thrombocythemia. Another study suggests that 
miR-342-3p may be involved in the B-cell transformation in CLL (Li et al. 2011). Its 
deregulation occurs in two esophageal carcinoma cell lines after 24- or 72-h treatment with 
cisplatin or 5-fluorouracil (Hummel et al. 2011).  
When the potential miRNA target genes were predicted by at least four of six 
databases, 81 candidate genes were identified; further pathway analysis showed involvement 
of these genes in eight biological networks such as the TGF-B pathway and BMP signaling. 
Interestingly, the role of both RGS17 and HIPK3—miR-363 target genes—has been 
investigated in drug response in numerous cancers like those of the prostate and ovary. 
RGS17 plays a critical role in T-cell proliferation and IL-2 production; lack of RGS17 results 
in impaired T-cell activation (Oliveira-Dos-Santos et al. 2000). The role of these genes in 
relation to their miRNA regulators should, however, be verified also in AML patients who 
have received chemotherapy. 
 
 
                  
 
 Figure 12. Relative expression levels of miR-363 and miR-532-5p in chemoresistant and chemosensitive AML 
patients.  
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CONCLUSIONS 
 
The work reported in this thesis seeks to identify miRNAs that can serve as prognostic and 
predictive markers in human cancers (CRC, GCTB, ALL, AML) by use of miRNA 
microarray. This microarray discriminated between cancer patients with differing responses 
to treatment and differing prognoses. To understand the pathogenesis behind miRNA 
changes, prediction of miRNA target genes and pathway analysis provided clues to the 
various biological processes underlying their progression and resistance to treatment. The 
results presented here confirm that miRNA profiling is an accurate method of discriminating 
between tumor subtypes.  
In addition to earlier recognized CRC- and KRAS-related miRNAs, we 
identified changes not previously described as CRC- and KRAS-associated. Four miRNAs 
(miR-127-3p, miR-92a, miR-486-5p, and miR-378) distinguished CRC patients who had the 
KRAS mutation from those with no mutation. The KRAS-related miRNAs and their target 
genes play a role in cell proliferation and apoptosis (Study I). Moreover, miRNAs (miR-31* 
and miR-592) associated with a response to anti-EGFR monoclonal antibody therapy were 
evident when the primary tumors were compared between anti-EGFR monoclonal 
antibodytreated chemorefractory mCRC patients with no mutation in KRAS and BRAF. 
Although the roles in drug response of up-regulated miR-31* and down-regulated miR-592, 
differentially expressed between patients with PD and DC, are not clear thus far, their 
potential target genes, SLC26A3 and ATN1, have shown some associations with drug 
response. Verification of SLC26A3 and ATN1 showed their levels to be lower in PD than in 
DC patients. Besides these findings, we evaluated the correlation of miRNA expression with 
overall survival, and this resulted in detection of 84 differentially expressed miRNAs 
between patients with poor and good prognosis by clustering and Cox proportional hazards 
regression model analyses in which two miRNAs, miR-140-5p and miR-1224-5p, were 
included in both analyses (Study II). 
In Study III, we aimed to recognize miRNAs which may be involved in 
progression and metastasis in GCTB, and miRNA profiling could distinguish primary tumors 
of metastatic tumors from those that were non-metastatic. By integration of the mRNA and 
miRNA expression data, we assessed whether any of the predicted miRNA target genes was 
in the list of mRNAs differentially expressed between metastatic and non-metastatic tumors; 
this resulted in identification of eight target genes.  
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In addition to doing verification of a higher level of NFIB by qRT-PCR in 
metastatic tumors, we also assessed its protein level by IHC in the same samples as well as in 
an independent validation cohort of GCTB samples. The expression of miR-136 and of both 
NFIB mRNA and protein was independent of other variables such as age, sex, size of tumor, 
or outcome, but a significant correlation appeared between NFIB expression and rate of 
metastasis. 
Our study on ALL (Study IV) did reveal miRNAs related to progression and 
survival for the first time. Comparison of the miRNA profiling of paired diagnosis-relapse 
samples showed miR-431 and miR-654-5p as differentially expressed miRNAs between 
them. Through the use of two different approaches, 31 miRNAs related to overall survival 
emerged. One of them, miR-423-5p, underwent further study, showing that those patients 
with no expression of miR-423-5p had a poorer prognosis independent of age, risk group, 
cytogenetic changes, or immunophenotype.   
To identify mechanisms underlying drug resistance in AML, the miRNA 
profiles of chemorefractory and chemosensitive diagnosed AML sample were compared 
which showed a response and were resistant to chemotherapy. Results indicated that three 
miRNAs (miR-363, miR-532-5p, and 342-3p) were differentially expressed between samples 
which were chemoresistant versus chemosensitive. The association of their potential target 
genes, ones such as RGS17, HIPK3, and ANKRD49, with treatment response and invasion 
was apparent. Some of the pathways affected by differentially miRNAs were the TGF-B 
pathway and BMP signaling (Study V). 
MiRNA microarray succeeded in assessing miRNA expression on a global scale 
and is an effective screening method to detect altered miRNA. This method allows assaying 
the expression level of hundreds of miRNAs in a single experiment. Moreover, miRNA 
profiling of FFPE samples by use of miRNA microarray provided reliable results. Therefore, 
miRNA microarrays can make an important contribution to both basic and applied research 
and have the potential to change the practice of medicine by providing the means for 
personalized diagnosis, cancer detection, and prognostic assessment (Yin et al. 2008). 
Genome-wide analysis of miRNA expression is, however, now largely sequencing based. 
Next generation sequencing (NGS) allows discovery of novel miRNAs in addition to known 
miRNAs and may replace some of the current microarray applications. 
In future, the prognostic and predictive biomarkers identified for the cancers 
studied in this thesis need to be validated in a larger set of samples using alternative 
approaches, and their roles in the mechanism of drug resistance and progression should be 
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explored by means of functional experiments. Identification of novel biomarkers provides an 
opportunity to develop cancer-treatment strategies to prevent unwanted drug side-effects and 
unnecessary medical costs. 
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